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This dissertation explores the effects of non-steroidal anti-inflammatory drugs 
(NSAIDs) on human colorectal cancer (CRC) cell proteins related to cellular structure 
and adhesion. NSAIDs are extensively used not only to treat inflammatory diseases but 
also to prevent cancer among high-risk groups. Their mechanisms are not fully 
understood, but both cyclooxygenase (COX) dependent and independent pathways 
play a role in NSAID-induced anti-tumorigenesis. Our lab previously reported that 
NSAIDs induce other anti-tumorigenic genes in a COX-independent manner (Chapter 
1). Human CRC cells treated with the NSAID sulindac sulfide (SS) showed dramatic 
morphological changes under differential interference contrast and fluorescent 
microscopy, as well as weakened cellular adhesion and loss of membrane permeability 
as measured by micro-impedance. To elucidate a molecular mechanisms involved, two 
independent microarray analysis were performed using HCT-116 cells, and the gene 
Nesprin-2 was selected for further study based on its novelty in relation to cancer and 
its role in cell organization and structure (Chapter 2). SS-treated cells diminished 
Nesprin-2 mRNA expression compared to vehicle-treated cells.  Other NSAIDs were 
also tested and demonstrated that inhibition of Nesprin-2 was not unique to SS. 
Additionally, immunohistochemistry showed higher levels of Nesprin-2 in the tumors of 
many tissue types in comparison with normal tissue. Further micro-impedance 
experiments on cells with reduced Nesprin-2 expression showed a proportional 
decrease in cellular adhesion. Next, we examined the effects of SS on another 
potentially oncogenic protein, epithelial cell adhesion molecule (EpCAM), which is over-
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expressed in many cancers including CRC, breast, pancreas, and prostate. We found 
EpCAM to be regulated by SS in a manner that is independent of: COX activity, 
transcription, de novo protein synthesis, and proteasomal degradation. Our findings 
demonstrate that SS drives an uncharacterized cleavage of EpCAM between arginine 
residues at positions 80 and 81 which is blocked by mutation to alanine residues as well 
as deletions (Chapter 3). Findings presented in this dissertation (1) our data suggests 
that Nesprin-2 maybe a potential novel cancer-associated protein and NSAIDs 
decrease its expression (2) SS facilitates proteolysis of EpCAM at amino acids 80/81 
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This dissertation explores the effects of non-steroidal anti-inflammatory drugs 
(NSAIDs) on human colorectal cancer (CRC) cell proteins related to cellular structure 
and adhesion. NSAIDs are extensively used over the counter to treat headaches and 
inflammation as well as clinically to prevent cancer among high-risk groups. Their 
mechanisms are not fully understood, but both cyclooxygenase (COX) dependent and 
independent pathways play a role in NSAID-induced anti-tumorigenesis. Our lab 
previously reported that NSAIDs induce other anti-tumorigenic genes including NSAID 
activated gene one (NAG-1) and activating transcription factor 3 (ATF3) (Chapter 1).  
Our goal was to shed further light on COX-independent activity by identifying, 
confirming, and characterizing novel NSAID targets related to cell structure and 
biogenesis in colorectal cancer cells. Human CRC cells treated with the NSAID sulindac 
sulfide (SS) showed dramatic morphological changes under differential interference 
contrast and fluorescent microscopy, as well as weakened cellular adhesion and loss of 
membrane permeability as measured by micro-impedance.  To elucidate molecular 
mechanisms involved, two independent microarray analyses were performed using 
HCT-116 cells and Nesprin-2 was selected for further study based on its novelty in 
relation to cancer and its role in cell organization and structure (Chapter 2). SS 
diminished Nesprin-2 mRNA expression to one third of the level observed in vehicle-
treated cells, as assessed by real-time PCR. Various other NSAIDs were also tested 
and demonstrated that inhibition of Nesprin-2 was not unique to SS. Additionally, 
immunohistochemistry showed higher levels of Nesprin-2 in the tumors of many tissue 
types in comparison with normal tissue. Further micro-impedance experiments on cells 
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with reduced Nesprin-2 expression showed a proportional decrease in cellular 
adhesion. Thus, our data suggest that Nesprin-2 may be a potential novel cancer-
associated protein and NSAIDs decrease its expression.  
Next, we examined the effects of SS on another potentially oncogenic protein, 
epithelial cell adhesion molecule (EpCAM), which is over-expressed in many cancers 
including CRC, breast, pancreas, and prostate. EpCAM is a type I transmembrane 
glycoprotein involved in adhesion. We found EpCAM to be down-regulated by SS in a 
manner that is independent of: COX activity, transcription, de novo protein synthesis, 
and proteasomal degradation. Our findings demonstrate that SS drives an 
uncharacterized cleavage of EpCAM between arginine residues at positions 80 and 81 
which is blocked by mutation to alanine residues as well as deletions (Chapter 3).  
Proteolysis of EpCAM by NSAIDs may provide a novel mechanism by which NSAIDs 
affect anti-tumorigenesis at the post-translational level. 
Findings presented in this dissertation suggest that Nesprin-2 is a potential novel 
oncogene and NSAIDs decrease its expression, and that SS facilitates proteolysis of 
EpCAM at amino acids 80/81 and provides a novel COX-independent mechanism of 
NSAID anti-tumorigensis at the post-translational level.
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CHAPTER 1  






Despite advancements in modern medicine, cancer is a major cause of death 
worldwide with a death toll of 7.6 million or about 13% of all deaths per year [1]. 
Colorectal cancer is the third most common cancer for both men and women [2]. Given 
this and the increasing life expectancies in the developed world, there are more 
chances of acquiring cancer, making research into mechanisms of colorectal cancer 
prevention a high priority. 
Non-steroidal anti-inflammatory drugs (NSAIDs) are a class of drugs which have 
been utilized for their analgesic and antipyretic effects since ancient times. In more 
recent history NSAIDs have also been widely used and studied for their anti-tumorigenic 
and chemopreventive properties. The classical pathway of action for NSAIDs is by 
blocking the generation of prostaglandins from arachidonic acid (AA) via inhibiting 
cyclooxygenase-1 and -2 (COX-1 and -2) activity. COX-1 is present and expressed 
constitutively in most tissues [3]. COX-2 expression is usually transient and can be 
quickly induced by: cytokines including TNF-α, IL-1, and IL-2, bacterial endotoxin 
lipopolysaccharide (LPS), tumor promoter phorbol myristate acetate (PMA), and growth 
factors [4-6]. NSAIDs, however, suffer from side effects including gastrointestinal tract 
bleeding and kidney failure which may be attributable to COX-1 inhibition [7, 8]. In 
addition, a recent clinical trial of familial adenomatous polyposis (FAP) patients 
observed  a  three-fold increase in the risk of cardio-toxicity from the COX-2 inhibitor 
celecoxib [9, 10]. These adverse side effects of COX inhibition are strong motivation 
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driving research into the many COX-independent mechanisms of NSAIDs. There is still 
much work to be done elucidating the pathways of COX-independent activity of NSAIDs 
and this area will be the primary subject of this chapter. 
 
1.2 Transcription Factors 
Transcription factors bind to specific DNA sequences in order to regulate gene 
expression either as activators or repressors and have a wide range of functions 
including development, response to environmental or intracellular signals, cell cycle 
control, and pathogenesis. NSAIDs have been shown to affect a wide variety of 
transcription factors including Egr-1, ATF3, CHOP, and Sp proteins. This section will 
summarize how these transcription factors are regulated by NSAIDs. 
 
1.2.1 Egr-1 
The zinc-finger DNA binding protein early growth respose-1 (Egr-1) is involved in 
many roles including differentiation and mitogenesis [11, 12]. In most tissue types, Egr-1 
is only expressed at low levels without stimulation. Egr-1 can be quickly induced by a 
number of signals including growth factors, mitogens, cytokines, stress, tissue damage, 
and differentiation factors [12].  Egr-1 has been demonstrated to act as a tumor 
suppressor in mouse two-step skin carcinogenesis studies using Egr-1 knock-out mice 
and has been shown to bind to the p53 promoter region both in vitro and in vivo [13]. 
Egr-1-dependent apoptosis is mediated by p53 in human melanoma cells [14].   
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Egr-1 is involved in apoptosis through a number of different pathways and 
apoptotic agents. Egr-1 plays an important role in up-regulating the anti-tumorigenic and 
pro-apoptotic protein NSAID activated gene-1 (NAG-1) protein expression in colorectal 
cancer cells during SS or other NSAID treatment [15]. NSAIDs also up-regulate Egr-1 
which translocates to the nucleus and binds to the promoter region of NAG-1 [16]. This 
observation has been confirmed in vivo using a Sprague-Dawley rat model for early 
colorectal tumorigenesis which utilizes the colon-specific pro-carcinogen 1,2-
dimethylhydrazine dihydrochloride (DMH) [17]. In this system Egr-1 and NAG-1 proteins 
where induced in rats treated with sulindac or celecoxib and DMH compared to rats only 
given DMH [17].  
Another conventional NSAID, tolfenamic acid (TA), induces Egr-1 at the 
transcription level via enhancement of epithelium-specific ETS transcription factor-1 
(ESE-1) nuclear translocation, which plays a role in activation of apoptosis in colorectal 
cancer cells [18]. Ultraviolet light-induced apoptosis in a mouse model is also 
dependent upon EGR-1 binding to the tumor suppressor PTEN’s 5’ un-translated 
region, and loss of EGR-1 in some cancers can result in radiation resistance [19].  
EGR-1 can also induce apoptosis and effect cell differentiation through the 
endoplasmic reticulum (ER) stress pathway via the ER stress agent thapsigargin, in a 
protein kinase-like endoplasmic reticulum kinase (PERK) expression dependent manor 
[20]. Egr-1 is also involved in neuronal apoptosis through transactivation of pro-
apoptotic BH3-only protein Bim gene expression [21]. In this rat model, Egr-1 has been 
shown to be both necessary and sufficient to mediate apoptosis of rat cerebellar granule 
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neurons [21]. In addition to NSAIDs, natural compounds such as resveratrol can also 
induce apoptosis via Egr-1, KLF4, and ATF3 [22].  
In contrast, depending on the cell type and conditions, Egr-1 can also play a 
negative role in tumorigenesis. In androgen-independent prostate cancer Egr-1 is 
required for mediating CXCL5/ENA78’s oncogenic activity on cell growth, migration, and 
epithelial-to-mesenchymal transition (EMT) via Snail stimulation, Cdk4 up-regulation, 
and inhibition of p27 [23]. Also, in human breast cancer cells EGR-1 mediated 
proliferation and survival is dependent on p300-dependent ATF5 acetylation [24].  
Thus, Egr-1 plays a complex role in tumorigenesis and progression acting though 
many pathways including both natural compounds and NSAIDs. Therefore, although 
NSAIDs have been shown to increase Egr-1 expression, further characterization of the 
details of NSAID-induced Egr-1 and its role in tumorigenesis is required. 
 
1.2.2 ATF3 
ATF-3 is a cyclic adenosine monophosphate (cAMP) dependent transcription 
factor that is a member of the bZIP family [25].  ATF3 is induced by the COX non-
selective NSAID SS, the COX-1 selective NSAID SC-560, the PPAR ɣ ligand 
troglitazone (TGZ), and the garlic derived diallyl disulfide (DADS) among others [26]. SS 
induces ATF3, C/EBP-homologous protein (CHOP), and NAG-1 [27]. Dominate 
negative protein kinase-like endoplasmic reticulum kinase (PERK) can inhibit SS 
induced NAG-1 [27]. However, dominant negative CHOP does not affect SS induced 
ATF3 protein expression, but does reduce SS induced NAG-1 expression [27]. Also, 
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anti-sense ATF3 blocks SS induced CHOP and NAG-1 protein expression [27]. Thus, it 
appears that CHOP is down-stream of ATF3 (Fig. 1.1). Phosphorlation of ATF2 also 
involved in NSAID up-regulation of ATF3 by increasing ATF3 promoter activity 
contributining to increased apoptosis in an ATF3-dependent manor in CRC cells treated 
with NSAIDs including TA [28]. 
Besides NSAIDs, 3,3′-Diindolylmethane (DIM), an indole-3-carbinol derivative 
from cruciferous vegetables, has shown  promising  in vivo anti-tumorigenic and pro-
apoptotic activity. DIM treatment induced apoptosis in CRC cells while inducing ATF3 
transcription and translation as well as increasing ATF3 promoter activity via over-
expression of ATF4 and binding of ATF4 to the ATF3 promoter region [29]. The natural 
compound resveratrol also induced apoptosis through the ATF3 pathway [22]. 
Over-expression of ATF3 in several cancer cell lines leads to induction of cell 
cycle arrest and inhibition of proliferation [30]. Also, ATF3 expression is reduced in 
human cancer tissue compared to adjacent normal tissue [31]. There are many studies 
showing a relationship between ATF3 and apoptosis. The PI3K inhibitor LY294002 
induces ATF3 and EGR-1 phosphorylation in a PI3K-independent manor in various 
CRC cell lines [32]. A nude mouse xenograft model using Ras transformed fibroblastes, 
either ATF3 -/- or ATF3 +/+, shows that ATF3 promotes cell death, arrests cell growth, 
and suppresses Ras-mediated tumorigenesis [33]. In prostate cancer cells Kruppel-like 
factor 6 (KLF6) has been demonstrated to bind to and activate the ATF3 promoter 
leading to apoptosis [34]. Both ATF3 over-expression and SS treatment down regulate 
metastasis-associated protein (MTA1) and β-catenin by real-time PCR in HCT-116 
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cells.  ATF3 over-expression and SS treatment decreased invasion in vivo, and ATF3 
over-expression resulted in smaller tumors in a mouse HCT-116 xenograft model  [26]. 
ATF3 has thus been implemented in several anti-tumorigenic pathways and represents 
one explanation for some of NSAIDs COX-independent activity. 
 
1.2.3 CHOP 
C/EBP-homologous protein (CHOP) is an ER stress response protein and 
member of the bZIP transcription factor family which inhibits CCAAT/enhancer-binding 
protein (C/EBP) and liver-enriched transcriptional activator protein’s (LAP) DNA-binding 
activity through the generation of heterodimers unable to bind DNA [35]. CHOP mRNA 
and protein levels are both elevated by SS treatment in colorectal cancer cells [27]. 
Celecoxib induces CHOP protein expression in malignant glioma cells, whereas SS 
requires carbonyl cyanide 4-(trifluoromethoxy)- phenylhydrazone (FCCP) co-treatment 
[36] to produce the same effect. FCCP is a protonophore which uncouples oxidative 
phosphorylation, causing the loss of mitochondrial membrane potential.  FCCP also 
does not induce CHOP protein by itself in malignant glioma cells [36, 37]. This suggests 
that mitochondrial disruption accompanied by endoplasmic reticulum stress response is 





Figure 1.1 NSAID and transcription factor interacti ons. 
NSAIDs cause ER stress which activates the ER membrane protein PERK. This results 
in PERK activating eIF2α through phosphorylation. P-eIF2α cause general translational 
arrest while at the same time stimulating ATF4 to translocate to the nucleus where 
ATF4 binds the promoter regions of ATF3 and CHOP. EGR-1 is up-regulated through 
both the PERK/ER stress pathway and by ESE-1 binding to EGR-1’s promoter region. 
EGR-1 in turn stimulates ATF3 up-regulation and EGR-1 binds to NAG-1’s promoter 
region. Dominate negative (DN) PERK will block NSAID activation of NAG-1. DN CHOP 
will not affect NSAID induced ATF3, but will reduce NSAID up-regulated NAG-1. Anti-






1.2.4 Sp Proteins 
 Specificity (Sp) proteins are zinc-finger transcription factors that are members of 
the Sp/KLF sub-family which also includes Kruppel-like factors [38]. Sp proteins bind to 
the GC and/or GT boxes of many promoter genes. There are several Sp proteins 
including: Sp1, Sp2, Sp3, Sp4, Sp5 [39], Sp6/KLF14 [39], Sp7 [40], and Sp8 [41]. This 
section will focus on Sp1, Sp3, and Sp4 which are phylogenetically more similar to one 
another than to the other Sp proteins [39, 42] and have been associated with changes 
in regulation of tumorigenesis in several studies.  
 Sp1 is normally responsible for controlling various housekeeping genes; 
however, Sp1 has also been linked to the regulation of tumorigenesis [43]. Sp proteins 
contribute to the proliferation of metastatic tumor phenotypes and thus overexpression 
of these transcription factors is a negative survival prognostic factor in many human 
cancers [43].  
TA has been shown to decrease Sp1, Sp3, and Sp4 protein expression as well 
as vascular endothelial growth factor receptor-1 (VEGFR-1) protein expression in 
pancreatic cancer cells [44]. Interestingly, small interfering RNA (siRNA) for Sp1, Sp3, 
and Sp4 also led to decreased VEGFR-1 [44]. Thus, TA decreases this important 
angiogenic factor via regulation of Sp proteins. This observation is supported by nude 
mouse data which shows that TA reduces Sp1, Sp3, and Sp4 protein expression in vivo 
as well. Also, vascular endothelial growth factor (VEGF) was demonstrated to be 
reduced by TA both in vitro and in vivo in this study  [45]. TA has also been shown to 
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decrease Sp1, Sp3, and Sp4 in rhabdomyosarcoma (RMS) cells and in lung cancer 
cells both in vitro as well as in mouse models [46, 47]. 
 COX-2 preferential NSAIDs including celecoxib also down-regulate Sp1 and Sp4 
activity in human colorectal cancer cells; however, Sp3 protein expression was 
unchanged in this case [48]. This action was shown to be through COX-2 independent 
activation of Sp1 and Sp4 proteasomal degradation [48]. Recently Dr. Safe’s group has 
shown that TA, and the novel nitric oxide (NO) chimera containing NSAID ethyl 2-((2,3-
bis(nitrooxy)propyl)disulfanyl)benzoate (GT-094), down-regulate Sp1, Sp3, and Sp4 in 
human CRC cells both in vitro and in a mouse xenograft model leading to decreased 
expression of multiple  proteins including: angiogenic VEGF and VEGFR-1, proliferation 
promoting cyclin D1 and hepatocyte growth factor receptor, cell survival proteins 
survivin and Bcl-2, and the pro-inflammatory gene products NFκBp65/p50 [49, 50]. The 
suggested mechanism for TA’s action on Sp proteins was through caspase activation. 
Thus, the COX-2 preferential NSAID celecoxib only decreased Sp1 and Sp4 in CRC 
cells while the conventional NSAID TA appeared to down-regulated Sp1, Sp4, and Sp3. 
Aspirin and its major sodium salicylate have also recently been shown to decrease Sp1, 
Sp4, and Sp3 in a caspase-dependent manor in human CRC in vitro as well as in a 
mouse model [51]. The addition of zinc sulfate inhibited aspirin-mediated apoptosis and 
Sp protein suppression, which suggests that aspirin’s cleavage of Sp proteins is 
dependent upon sequestration of zinc ions  [51]. Taken together this data shows that a 
wide variety of NSAIDs of varying COX specificity all down-regulate Sp proteins in 
several different cancers including pancreatic, lung, rhabdomyosarcoma, and colon. 
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The consistency of these results across these experiments makes NSAID action 
through Sp protein regulation a promising pathway. 
 
1.2.5 SMAD proteins 
Human SMAD proteins are homologs of both the Caenorhaditis elegans small 
body size (SMA) protein and the Drosophila melanogaster mothers against 
decapentaplegic (MAD) protein which is regulated by maternal effect enhancement of 
weak decapentaplegic alleles [52]. Thus, the nomenclature SMAD is a portmanteau of 
SMA and MAD. SMAD transcription factors are key regulators of the TGF-β signaling 
pathway and normally form heteromeric complexes of SMAD members which 
translocate to the nucleus and regulate gene expression through binding with other 
transcription factors, co-repressors, or co-activators [53]. SMAD is another example of 
the tissue specificity and the complex effects of specific micro-environments on the 
outcome of expression of a given protein. In early stages of tumorigenesis, SMAD 
signaling can have tumor suppressive effects, while helping to drive metastasis in late 
stage cancers [54].  A vast array of proteins are effected by the SMAD pathway and 
many of these are linked to cell migration and invasion of cancer cells [55]. Thus, SMAD 
signaling in advanced stage tumorigenesis is a promising target for cancer treatment.  
The salicylic acid derivative 5-aminosalicylic acid (5-ASA) has been 
demonstrated to inhibit TGF-β-mediated SMAD2/3 phosphorylation and subsequently 
suppress nuclear translocation of SMAD2/3 in human colorectal cancer cell [56]. A 
recent large case-control study of colon and rectal cancer patients observed genetic 
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variation of TGFβ/SMAD pathway genes; this study suggests that the use of 
aspirin/NSAIDs modulates cancer risk associated with SMAD genes [57]. A recent 
finding from our lab demonstrates that TA inhibits TGF-β-induced SMAD 
phosphorylation through the ERK MAP kinase pathway, Fig. 1.3, in various cancer cells 
[58]. TA showed the strongest reduction of phosphorylated SMAD2 in a screen of 
NSAIDs including several examples of conventional, COX-1 preferential, and COX-2 
preferential NSAIDs [58]. The interference of SMAD signaling by NSAIDs represents a 
promising mechanism of anti-tumor action. 
 
1.3 Cell Membrane Proteins 
Cell membrane proteins are a diverse group of proteins that perform a wide 
variety of functions. Some are adhesion modules responsible for cell-cell binding, while 
others are responsible for anchoring the plasma membrane to the actin cytoskeleton. 
Cell surface proteins can act as receptors for paracrine and autocrine cell signaling and 
are responsible for signal transduction into the cytoplasm and even translocation into 
the nucleus to effect transcription. Lipid rafts provide the scaffolding for many different 
protein-protein interactions in, on, and under the plasma membrane. Over-expressed 
membrane proteins are a highly studied area due to their potential prognostic value 




Epidermal growth factor receptor (EGFR) is a single pass receptor tyrosine 
kinase which is mutated and/or over-active in a high percentage of cancers. EGFR 
signaling is down-stream of the cyclooxygenase pathway and production of PGE2. 
EGFR signaling can lead to cell proliferation through the Erk1/2 pathway and/or cell 
survival, invasion, and angiogenesis through the AKT pathway. EGFR is the target of 
approved CRC treatments including the EGFR soluble decoy receptor fusion protein 
Ziv-Aflibercept and the mouse/human chimeric monoclonal antibody Cetuximab which 
can bind to and shut-off mutated EGFR that is functioning with or without growth factor 
signaling. Sulindac metabolites, sulindac sulfide and sulindac sulfone, down-regulate 
EGFR signaling through inhibiting activation and expression of EGFR in CRC cell lines 
[59]. The dual NSAID Licofelone, inhibits both COX and 5-lipoxygenase (5-LOX), has 
been shown to decrease CRC membrane fluidity leading to the inhibition of EGFR 
signaling which contributes to apoptosis [60]. NSAIDs could be another attractive 
method to target EGFR and the negative side-effects of COX inhibition could be 





Figure 1.2 NSAIDs’ effect on the EGFR pathway. 
NSAIDs such as sulindac sulfide down-regulate EGFR protein expression. Also, 
NSAIDs block phosphorylation of EGFR necessary for activation of down-stream EGFR 
signaling. EGFR pathways include cell cycle progression, increased cellular growth, and 
increased cell survival and resistance to apoptosis. 
 
1.3.2 E-cadherin 
E-cadherin is a calcium-dependent type-1 transmembrane protein. It is important 
for tight cell-cell junctions and anchors to the cytoskeleton. E-cadherin can play an 
important role in tumor progression through its sequestration of β-catenin to the plasma 
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membrane which prevents β-catenin from acting in the Wnt signaling pathway and for 
its job function as a cell adhesion molecule. Loss of E-cadherin function and/or 
expression is an important step in EMT leading to invasion and migration. Soluble E-
cadherin (sEcad) may have oncogenic activity in cutaneous squamous cell carcinomas 
via association with the HER/IGF-1R-family receptors and activation of MAPK and 
PI3K/mTOR pathways [61]. In an animal model study, sulindac treatment protected 
APCMin/+ mice from E-cadherin loss and accumulation of nuclear β-catenin in colon 
tumors [62]. The non-selective NSAID indomethacin reduced protein levels of E-
cadherin and collagen IV while increasing the activity of  matrix metalloprotease-9 
(MMP-9) leading to enhanced motility in vitro in lung cancer cell lines [63]. This may be 
an example where cancer type and stage is critical to treatment outcome. Through the 
course of invasion and metastasis cancer cells first need to lose their tight cell-cell 
adhesion to allow the cells to travel through the vascular and/or lymphatic system; then 
in order to establish a new colonies, the cancer cells will need to re-establish tight 
junctions at the metastasis sites. This creates a complex situation when targeting 
dysregulated cell adhesion molecules. 
 
1.4 Cytoskeletal Proteins 
Cytoskeletal proteins are critical for maintaining normal cell form and function. 
They represent the highways for vesicle trafficking which is a key element of autocrine 
and paracrine cellular signaling. Cytoskeletal protein rearrangement is also critical part 
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of cell migration. All of these aspects are areas which would need to be dysregulated to 
allow a pre-cancerous cell to go through EMT and metastasize to a new disease site. 
 
1.4.1 Thymosin β-4 
Thymosin β-4 is a member of the β-thymosins family of highly conserved 5 kDa 
peptides which are involved in actin sequestration and normal cell migration as well as 
aberrant tumor metastasis [64]. Thymosin β-4 over-expression in SW480 CRC cells has 
also been shown to assist immune evasion and resistance to anticancer therapy; this 
process involves FasL-bearing T cells and to the topoisomerase II inhibitors doxorubicin 
and etoposide which down-regulate Fas and up-regulate Survivin expression [65]. COX-
1 preferential NSAIDs such as indomethacin and SC-560 induce thymosin β-4 while the 
conventional NSAID SS does not induce thymosin β-4 [66]. Induction of oncogenes 
such as thymosin β-4 by some but not all NSAIDs could be one explanation for the 
varied outcomes of treatment with different NSAIDs. 
 
1.4.2 Actin Stress Fibers 
Actin stress fibers are the prominent contractile structures in most tissue cultures 
and consist of bundles of actin filaments, crosslinking proteins, and myosin II motors 
[67]. They are key factors in contractility and cell motility which are needed for 
morphogenesis and cellular adhesion [67]. Non-motile cells tend to have thick and fairly 
stable stress fibers, whereas motile cells usually have thinner and fewer actin stress 
fibers which are very dynamic [68]. Many developmental and physiological processes 
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depend on the proper regulation of actin cytoskeleton, and dysregulation can lead to 
pathological conditions such as myofibrillar myopathies, neurological disorders, and 
cancer [69]. 
SS, as well as the phenolic antioxidant caffeic acid phenethly ester (CAPE) at 
sub-apoptotic doses of each, causes cytoskeletal reorganization, loss of actin stress 
fibers, and loss of focal adhesion plaques in human colon carcinoma cells [70]. The 
COX-1 specific NSAID indomethacin and the COX-2 specific NSAID NS-398 reduced 
actin stress fibers in wounded gastric epithelial cells [71]. Indomethacin also causes 
dramatic morphological changes including time and dose dependent loss of stress 
fibers in lung cancer cell lines [63]. The COX-1 preferential NSAIDs indomethacin and 
SC-560 cause cytoskeletal reorganization in HCT-116 CRC cells [66]. It appears that 
NSAIDs affect actin stress fibers in a range of cancer types regardless of 
cyclooxygenase preference for COX-1, COX-2, or a lack of preference. This is one 





 Transforming growth factor β 1 is a TGF-β superfamily member that is a secreted 
soluble polypeptide involved in many cellular processes such as cell growth and 
proliferation as well as apoptosis. Complexes are formed by TGF-β family members 
binding to type I and type II receptors [72]. TGF-β uses endothelial specific ALK1 and 
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ALK5 type I receptors, the type II receptor TGFBR2, and the co-receptors β-glycan and 
endoglin [73]. 
The conventional NSAID naproxen sodium lowered serum TGF-β1 levels and 
interfered with healing in rats with fractured tibias. However, rats co-treated with 
naproxen sodium and granulocyte colony stimulating factor (G-CSF) did not have 
lowered TGF-β1 levels and did not impede fracture healing [74]. This suggests that 
TGF-β1 may be responsible for the inhibition of fracture healing that many NSAIDs 
cause. In a swine model for thoracic surgery the COX-2 preferential NSAID diclofenac 
reduced the amount of TGF-β in the pleural effusion caused by mechanical pleural 
abrasion, and the diclofenac group also had reduced pleural effusion volume, white cell 
count, and protein content [75]. However, the non-selective NSAID ketorolac and the 
COX-1 favoring NSAID indomethacin had no effect on TGF-β expression and bioactivity 
in rat osteoblast-enriched cultures [76]. It is very common for cancers to have TGF-β 
receptors which are mutated and always active regardless of the presence or absence 
of ligand; in these cases regulating TGF-β ligands would be not be effective and the 






Figure 1.3 NSAIDs’ effect on the TGF- β/SMAD pathway. 
TGF-β ligand binds to a type II receptor (TβRII) dimer then recruits a type I receptor 
(TβRI) dimer and forms a heterotetrameric complex with the ligand. This complex 
phosphorylates SMAD2/3 and the SMAD complex translocates to the nucleus to initiate 
down-stream targets. NSAIDs reduce TGF-β1 serum levels in vivo. NSAIDs, especially 
tolfenamic acid, stimulate the MEK-ERK pathway which inhibits C-terminal 
phosphorylation of SMAD2/3, thus blocking nuclear translocation of SMAD2/3. The 
MEK1/2 inhibitors PD98059 and U0126 partially restore SMAD2/3 phosphorylation in 
the presents of NSAIDs. This suggests that NSAIDs also stimulate the MEK-ERK 




 Non-steroidal anti-inflammatory gene 1 (NAG-1 also known as GDF-15) is a 
divergent member of the TGF-β superfamily. The pro form of NAG-1 is cleaved at the 
RXXR amino acid site to free the 112 amino acid mature form from the C-terminal 
region [72]. Mature secreted NAG-1 forms a homodimer utilizing the seventh cysteine 
residue to form a disulfide bridge while the first six cysteine residues may form a 
cysteine knot which is common in the TGF-β superfamily [72]. NAG-1 is one of the few 
TGF-β proteins whose receptors remain unknown.  
NAG-1 is the downstream target of three major tumor suppressor pathways 
including p53, Egr-1, and GSK-3β [77, 78]. NSAIDs such as SS induce NAG-1 protein 
expression at the transcriptional level via Egr-1 transcription factors [15, 79]. NSAIDs 
up-regulate Egr-1 in vitro and in vivo, which translocates to the nucleus and binds to the 
promoter region of NAG-1 [16, 17]. This Egr-1 stimulation appears to be a down-stream 
result of increased protein expression of ESE-1 [18]. SS induced NAG-1 can be blocked 
by dominate negative PERK and by dominant negative CHOP, though dominant 
negative CHOP does not block ATF3 induction [27]. Interestingly anti-sense ATF3 
inhibits SS induced CHOP and NAG-1 protein expression [27]. This suggests that NAG-
1 is down-stream of CHOP which is down-stream of ATF3 which is down-stream of 
PERK which is down-stream of SS. NAG-1 is involved in many pro-apoptotic pathways 




1.6 Summary Conclusion 
 NSAIDs interact with many pathways in human colorectal cancer. There are 
many promising cyclooxygenase-independent mechanisms utilized by NSAIDs which 
provide potential avenues for developing new and better drugs that minimize or 
eliminate the undesirable side effects of cyclooxygenase inhibition such as gastric 
bleeding and cardiovascular risks.  
NSAIDs up-regulate a number of transcription factors such as the tumor 
suppressors Egr-1, ESE-1, ATF3, CHOP, and p53. Tumorigenic cell growth and survival 
stimulating transcription factors such as Sp1, Sp3, and Sp4 are also down-regulated by 
NSAIDs. The often oncogenic cell membrane protein EGFR is down-regulated by 
NSAID treatment in CRC cell lines.  The cell adhesion protein E-cadherin is protected in 
APCMin/+ mice from loss expression by NSAID treatment. NSAIDs cause cytoskeletal 
reorganization, loss of actin stress fibers, and up-regulate the actin sequestration 
protein thymosin β-4. The secreted protein TGF-β1 is decreased by NAIDS in vitro and 
in vivo. NSAIDs also impact the TFG-β pathway down-stream of TFG-β1 by inhibiting 
phosphorylation of SMAD2. This could be useful for situations where TFG-β receptors’ 
activity is no longer ligand dependent due to mutation. The secreted tumor suppressor 
protein NAG-1 is induced by NSAIDs both in vitro and in vivo via p53, Egr-1, and GSK-
3β and other pathways. NSAIDs and improved derivatives of NSAIDs have great 





CHAPTER 2  
NONSTEROIDAL ANTI-INFLAMMATORY DRUG SULINDAC SULFID E 
SUPPRESSES STRUCTURAL PROTEIN NESPRIN-2 EXPRESSION IN 





The results discussed in this chapter have been published in Biochimica et Biophysica 
Acta (BBA) - General Subjects, Volume 1840, Issue 1, January 2014, Pages 322-331. 
2.1 Abstract 
Aims: 
Nonsteroidal anti-inflammatory drugs (NSAIDs) are well known for treating inflammatory 
disease and have been reported to have anti-tumorigenic effects.  Their mechanisms 
are not fully understood, but both cyclooxygenase (COX) dependent and independent 
pathways are involved. Our goal was to shed further light on COX-independent activity. 
 
Main methods: 
Human colorectal cancer cells were observed under differential interference contrast 
microscopy (DICM), fluorescent microscopy, and micro-impedance measurement. 
Microarray analysis was performed using HCT-116 cells treated with sulindac sulfide 
(SS). PCR and western blots were performed to confirm the microarray data and 
immunohistochemistry was performed to screen for Nesprin-2 expression. The micro-
impedance experiment was repeated including Nesprin-2 knock-down by siRNA. 
 
Key findings: 
HCT-116 cells treated with SS showed dramatic morphological changes under DICM 
and fluorescent microscopy, as well as weakened cellular adhesion as measured by 
micro-impedance. Nesprin-2 was selected from two independent microarrays, based on 
its novelty in relation to cancer and its role in cell organization. SS diminished Nesprin-2 
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mRNA expression as assessed by reverse transcriptase and real time PCR. Various 
other NSAIDs were also tested and demonstrated that inhibition of Nesprin-2 mRNA 
was not unique to SS. Additionally, immunohistochemistry showed higher levels of 
Nesprin-2  in many tumors in comparison with normal tissues. Further micro-impedance 




Our data suggest that Nesprin-2 may be a potential novel human cancer-associated 





Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used in the treatment 
of inflammatory disease through inhibition of prostaglandin production by 
cyclooxygenase-2 (COX-2). Interestingly, COX-2 expression is up-regulated in human 
colorectal tumors and regulates tumor growth in animal models [80-82]. NSAIDs have 
been shown to inhibit incidence and mortality of colorectal cancer in a broad range of 
studies [83, 84]. Although the chemopreventive and anti-tumorigenic activity of NSAIDs 
in cancer is well established, the molecular mechanisms responsible have not been 
completely elucidated. 
The NSAID sulindac sulfide (SS) inhibits growth of tumors in azoxymethane-
induced rat colon models [85], suppresses intestinal polyp formation in  APC/Min mice 
[86, 87], down-regulates β-catenin protein apoptosis [88], and induces apoptosis under a 
number of experimental conditions [89-91]. SS has been shown to change colorectal 
cancer cell morphology [92], alter cytoskeletal organization, and cause loss of actin 
stress fibers [93, 94]. This is probably due to a dose-dependent reduction of tyrosine 
phosphorylation of focal adhesion kinase  [94]. It has also been demonstrated that SS 
reduces cell migration and invasion in mouse models and human colorectal cell lines 
[95, 96].  
We speculated that SS alters gene expression related to cell organization, and 
subsequently we found the structural gene Nesprin-2 (NUANCE/Syne-2) was down-
regulated in two independent microarrays  using two different doses of SS-treated 
human colorectal cancer cells. Nesprin-2 is a giant protein with an α-actin-like actin 
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binding domain [97]. To date, together with the closely related Enaptin/Nesprin-1, 
Nesprin-2 is the largest of the α-actin superfamily, and it encodes a 796 kDa protein 
containing an N-terminal actin-binding domain, central coiled-coil rod domain, and a C-
terminal transmembrane domain [97, 98]. Nesprin-2 also has many truncated alternate 
splicing forms [99, 100]. The majority of Nesprin-2 is localized to the nuclear envelope, 
while a very small fraction can be found in the cytoplasm; the tissue distribution of 
Nesprin-2 mRNA is fairly ubiquitous with most tissues, showing at least trace amounts 
[97]. Recently Nesprin-2 has been shown to affect nuclear size and to be involved in 
regulating genes during wound healing [101, 102]. This colossal protein contains 
multiple binding sites and serves as a framework for protein complexes on the nuclear 
envelope [103, 104].  
In this study, we found that human colorectal cancer HCT-116 cells dramatically 
changed their morphology and cell adhesion by treatment with SS, as assessed using 
biological, chemical, optical, and electrical methods. Subsequently, Nesprin-2 was 
identified and confirmed as being down-regulated by SS. Finally, we showed that 
Nesprin-2 is more highly expressed in tumor tissues, compared to normal tissues, 
suggesting that Nesprin-2 may be a novel cancer-associated protein.  
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2.3 Materials and Methods 
 
2.3.1 Reagents 
The NSAIDs used in this study were purchased as follows: SS, TA, and SC-560 
from Cayman Chemical Company (Ann Arbor, Michigan); diclofenac from Sigma-Aldrich 
(St. Louis, MO); 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-ethylsulfonyl)phenyl-2(5H)-
furanone  (DFU) was as a gift from Merck (Rahway, NJ). All other chemicals were 
purchased from Fisher Scientific, unless otherwise specified. 
 
2.3.2 Cell Culture 
All cells were purchased from ATCC and grown at 37oC with 5% CO2. HCT-116 
and HT-29 cells were cultured with McCoy’s 5A modified. HCT-116 cells were kept to 
fewer than 20 passages to maintain the expected cellular mutations. SW480 cells were 
cultured with RPMI-1640. All culture media was supplemented with 10% fetal bovine 
serum, 100 µg/ml streptomycin, and 100 UI penicillin. Serum free media was used for all 
SS and vehicle treatments unless stated otherwise. 
 
2.3.3 Microscopic Measurement 
Three microscopic techniques were employed, differential interference contrast 
microscopy (DICM) and epi-fluorescence microscopy (EFM) for imaging the whole cell 
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including dorsal surface, as well as interference reflection contrast microscopy (IRCM) 
for imaging the ventral surface of cells.  
The microscopic imaging system consisted of an Olympus IX-71 inverted 
microscope, a plan apochromat 100 x oil immersion objective with adjustable numerical 
aperture, 14-bit electron multiplier charge coupled device from Hammamatsu, and an 
incubation chamber that kept the temperature (37°C), humidity, and CO2 (5%) levels 
constant. In order to examine the entire cellular morphology response to SS using DICM 
and EFM, HCT-116 cells were plated at a concentration of 1x105 cells/ml. After 24 hr, 
cells were stained with LavaCell™ solution (Active Motif, Carlsbad, CA) to a 
concentration of 0.6 µM for 6 hr. Next, the media was changed to serum-free media 
containing 30 µM SS, and the cells were monitored microscopically for the next 6 hr.  
IRCM was used to examine the bottom morphology changes of HCT-116 cells exposed 
to 10 µM and 30 µM SS. 
 
2.3.4 Electrical Impedance Measurements 
A data acquisition and analysis system was implemented using LabVIEW 
(National Instruments, Austin, TX). Preliminary naked scans were performed to optimize 
sensitivity and to check for any electrode debris or defects. The electrodes were then 
inoculated with 400 µL media containing HCT-116 cells at a concentration of 2.4x104 
cells/ml under a range of SS concentrations. During the cellular micro-impedance 
scans, data was acquired at a rate of 32 Hz for 16 sec using a 30 ms filter time constant 
and 12 dB/decade roll off for approximately 96 hr.  Averages and standard deviation 
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estimates were obtained from 512 sampled data points over the 16 sec time intervals. 
During the experiments cell-inoculated electrodes were kept in a cell culture incubator. 
 
2.3.5 Microarrays 
Two independent microarray experiments were performed: Human Array-Illumina 
HEEBO oligo microarray and Agilent oligo microarray. The 48.5K Human Array-Illumina 
HEEBO oligo microarray was purchased from Microarrays Inc (Nashville, TN). RNA was 
isolated from DMSO or 5 µM treated HCT-116 cells after 24 hr. One microgram of total 
RNA was used to synthesize cDNA. The arrays were hybridized at 42°C for 12-16 hr in 
a humidified hybridization chamber (GenomicTree, Korea). After washing microarrays 
were immediately dried using the microarray centrifuge (GenomicTree, Korea). The 
hybridization images were analyzed by GenePix Pro 6.0 (Axon Instruments, Sunnyvale, 
CA).  
Another microarray analysis was conducted using Agilent human oligo 1A arrays 
(Agilent Technologies, Palo Alto, CA). HCT-116 cells were treated with DMSO or 10 µM 
SS for 24 hr. Total RNA was amplified using the Agilent Low RNA Input Fluorescent 
Linear Amplification Kit protocol.  Starting with 500 ng of total RNA, Cy3- or Cy5-labeled 
cRNA was produced according to manufacturer’s protocol. For each two color 
comparison, 750 ng of each Cy3 and Cy5 labeled cRNAs were mixed and fragmented 
using the Agilent In Situ Hybridization Kit protocol. Hybridizations were performed using 
the Agilent 60-mer oligo microarray processing protocol. Data was obtained using 
Agilent Feature Extraction software v7.5. Intensity plots were generated for each ratio 
 
 33 
experiment, and genes were considered “signature genes” if the p value was less than 
0.001. Functional annotation of genes was performed according to the Gene Ontology 
Consortium (http://www.geneontology.org/index.shtml) by GeneSpring v7.3. 
 
2.3.6 Reverse Transcriptase PCR and Real Time PCR 
RNA was isolated from cell cultures using Qiagen’s RNeasy Mini Kit following the 
manufacturer’s protocol. One microgram of RNA was used to generate cDNA using 
BIORAD’s iScript™ cDNA Synthesis Kit following the manufacturer’s protocol. PCR was 
performed with the following primers:: Nesprin-2 Giant forward 5’- 
CAGTCCTTACAACTCCTGGGACAC-3’, Nesprin-2 Giant reverse 5’-
GACTGATTCTCCTACCCACAGACTC-3’; Nesprin-2 all isoforms  forward 5’-
TCACAGAGCAGCAGTCAGGT-3’, Nesprin-2 all isoforms reverse 5’-
GCTCACGTTGACAGAGACCA-3’; Nesprin-2 α1 forward 5’-
GGAAGACCCCAGAGAAATCC-3’, Nesprin-2 α1 reverse 5’-
CCTGTCACCTTCCATTTGCT-3’; Nesprin-1 forward 5’-
GGCTGAAAATCGAAGAGACG-3’, Nesprin-1 reverse 5’-CATCTC 
TGTGAGCCAGACCA-3’; GAPDH forward, 5’-GGGCTGCTTTTAACTCTGGT-3’, 
GAPDH reverse 5’-TGGCAGGTTTTTCTAGACGG-3’; IDH2 forward 5’-
GACGGAGATGTGCAGTCAGA-3’, IDH2 reverse 5’-GTCCGTGGTGTTCAGGAAGT-3’; 
NAG-1 forward 5’-CTCCAGATTCCGAGAGTTGC-3’, and NAG-1 reverse 5’-
AGAGATACGCAGGTGCAGGT-3’. Densitometric analysis of reverse transcriptase 
PCR was performed using Scion Image software (Frederick, MD). Real Time PCR was 
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performed using Thermo Scientific’s Absolute qPCR SYBR Green Mix (Waltham, MA) 
on a Bio-Rad MyiQ iCycler thermal cycler using Bio-Rad iQ5 version 2.1 software 
following the manufacture's protocol (Hercules, CA). Measurements were standardized 
using GAPDH, and each set of three or more trials was averaged.  
 
2.3.7 Immunohistochemistry 
Immunostaining on a Biochain Tissue Array Human Tumor Tissue II (Lot# 
A711214) slide was performed using standard immunohistochemistry procedures 
(T8235713-2; Newark, CA). The slide was incubated overnight at 4°C with undiluted 
mAB K20-478 hybridoma antibody against Nesprin-2 [97] and secondary antibody 
treatment was performed using biotinylated anti-mouse immunoglobulins from 
BioGenex (HK-335-9M; San Ramon, CA). Nesprin-2 protein was stained brown with 
Chromogen-DAB solution and cells were counterstained with Hematoxylin (Richard 
Allen Scientific, Kalamazoo, MI). Tissues were rated for stain intensity by microscopic 
examination of three observers. An Olympus BX41 microscope with an Olympus DP70 
digital camera employing integrated software was used for image capture/scaling.  
 
2.3.8 Transfection of Nesprin-2 siRNA 
HCT-116 cells were transfected with siRNA using PepMute reagent for 24 hours 
(SignaGen, Rockville, MD) following the manufacturer’s protocol.  The final 
concentration of siRNA was 10 nM for both the Control siRNA-A, sc-37007, and Syne-2 
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siRNA, sc-61630 (Santa Cruz Biology, Inc., Santa Cruz, LA). After 24 hours the media 
was changed with fresh complete media and allowed to grow for 24 more hours. The 
cells were then suspended and diluted to 2.4x104 cells/ml with McCoy’s 5A modified 
media. Cells were then treated with either DMSO or 30 µM SS. These cells were used 
for impedance experiments and harvested to isolate RNA for real time PCR.  
The cells were suspended and diluted to 2.4x104 cells/ml with McCoy’s 5A modified 
media. Cells were then treated with either DMSO or 30 µM SS. These cells were used 
for impedance experiments and harvested to isolate RNA for PCR.  
 
2.3.9 Western Blot 
Cells lysates were isolated in RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM 
NaCl, 1 mM EDTA, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS) 
supplemented with protease inhibitors (1mM PMSF, 1 µg/mL aprotinin, 1 µg/mL 
leupeptin) and phosphatase inhibitors (10 mM NaF, 0.1 mM Na3VO4,).  Protein 
concentration was determined by BCA protein assay (Pierce, Rockford, IL). The 
proteins were separated on SDS–PAGE and transferred to nitrocellulose membranes 
(Osmonics, Minnetonka, MN). The membranes were incubated with anti-Nesprin-2 (sc-
51220, Santa Cruz Biotechnology, Inc., Santa Cruz, CA) in 1% bovine serum albumin at 
4°C overnight. After three washes with tris buffered saline containing 0.05% Tween 20, 
the blots were incubated with peroxidase-conjugated IgG for one hour at room 
temperature and visualized using ECL (Amersham Biosciences, Piscataway, NJ) and a 




Unless stated otherwise statistical significance was determined using single-
tailed paired Student t tests. P-values are noted with asterisks as follows: *P < 0.05, **P 
< 0.01, and ***P < 0.001. 
 
2.4 Results 
2.4.1 SS Treatment Alters Cell Morphology and Interferes with Cell Adhesion in 
HCT-116 cells 
Micro-impedance measurements were used to quantitatively examine relative 
changes in proliferation and morphology, due to the modulations in cell-cell adhesion, 
cell-substrate adhesion, and plasma membrane capacitance under different 
concentrations of SS. It is well known that NSAIDs alter cell morphology and adhesion 
in cell culture [94]. Resistance and reactance are both measured as functions of time 
and AC frequencies; Fig. 2.1A and B present results only at representative frequencies 
of 5.62 kHz and 100 kHz, respectively. These changes are represented as the induction 
of apoptosis [105, 106]. Higher concentrations of SS produced a reduction in the 
normalized impedance components reflecting changes in cell-cell adhesion, and cell-
substrate adhesion (resistance, Fig. 2.1A), and the capacitance of the plasma 
membrane (Reactance, Fig. 2.1B). This data demonstrates the suppression of cell-cell 
and cell-substrate adhesion by SS in a dose and time dependent manner. To examine 
cellular morphology HCT-116 cells were treated with SS in the presence of LavaCell 
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staining solution, which stains only cytoplasm and the nuclear membrane and is not 
cytotoxic under these conditions. As shown in Fig. 2.1C, SS changes cell morphology 
causing cellular rounding and nuclear condensation. Interestingly the apoptotic feature, 
“blebbing”, can be clearly seen under SS treatment (Fig. 2.1C, arrows). IRCM imaging 
shows dynamic gap morphology responses of live cells under SS treatment; dark areas 
indicate tight focal adhesion points between cell and substrate while lighter areas show 
increased gap between cell and substrate (Fig. 2.1D). Higher concentrations of SS 
showed a more dramatic increase in cellular gap from substrate and most bottom 
contacts including the close contacts as well as the remaining brighter areas noticeably 
diminished in response to the cellular shrinkage and retraction caused by SS, while 
some of the tightest focal contacts remain along the periphery of cells (Fig. 2.1D). Thus, 





Figure 2.1 HCT-116 cell adhesion and morphology dur ing SS treatment. 
Biosensors were used to examine the dynamic attachment and spreading of colorectal 
cancer cells by monitoring micro-impedances. (A) The corresponding normalized 
resistance of HCT-116 cells. (B)  The corresponding normalized reactance of HCT-116 
measured for the same cells. The terms R and X represent the resistance and 
reactance, respectively, and the subscripts c and n indicate cell covered and naked 
scans, respectively. Symbols represent 20 data intervals. (C) Cellular morphology of 
HCT-116 cells was observed during 6 hr, 30 µM SS treatment in a real time manner. 
Observations were made using DICM and EFM.  LavaCell (0.6 µM) was used for 
staining cytoplasm & membranes. The arrows indicate apoptotic blebbing. Scale bars 
represent 10 µm. (D) IRCM images to examine cellular gap morphology responses of 




2.4.2 Cell Organization and Biogenesis Genes Pathways are Down-Regulated by 
SS 
To elucidate molecular mechanisms by which SS affects cell morphology two 
independent microarray experiments were performed and compared. The genes of 
interest using SS-treated HCT-116 cells were chosen for function in “cellular 
organization and biogenesis” using the Gene Ontology Consortium. Surprisingly, only 
two genes, isocitrate dehydrogenase 2 (IDH2) and Nesprin-2, were commonly down-
regulated in the category of Cell Organization and Biogenesis and no genes were 
commonly up regulated between these two microarrays in this category (Table 2.1). 
These genes represent potential targets of SS. IDH2 is a mitochondrial isozyme and 
Nesprin-2 is a large structural protein. Nesprin-2 was selected for further study based 
on its higher fold reduction compared to IDH2 and its unique role as a link between the 
actin cytoskeleton and the nuclear envelope as well as its novelty in relation to cancer. 
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Table 2.1 Cell organization and biogenesis genes do wn-regulated by sulindac 
sufide 
Two independent oligo microarray experiments were performed on HCT-116 cells, 
treated by either 5 µM or 10 µM of sulindac sulfide (SS). Functional annotation of genes 
was performed according to Gene Ontology Consortium by GeneSpring 7.3. The two 
microarrays were compared for commonly up- and down-regulated genes in the 
categories of cell organization and biogenesis. The only two common genes with a cut 
































2.4.3 Confirmation of Sulindac Sulfide Microarray Data 
Down-regulation of Nesprin-2 and IDH2 mRNA by SS was confirmed by PCR in 
three replicates, standardized to GAPDH as a positive control (Fig. 2.2A). The fold 
reductions in these two genes correlates with the microarray data in that Nesprin-2 is 
more strongly down-regulated than IDH2 in both cases. We also examined NAG-1 
(positive control) and Nesprin-1 expression. NAG-1 has been known to be induced by 
SS [107] whereas Nesprin-1 is another form of Nesprin family proteins.  
Interestingly Nesprin-1 did not show any alterations in the presence of SS (Fig. 
2.1A) indicating that NSAIDs affect Nesprin-2 in a specific manner. As shown in Fig. 
2.1A Nesprin-2 repression was significant at p< 0.001 and IDH2 was reduced at p < 
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0.05. Protein expression of truncated Nesprin-2 forms was checked by western blot to 
verify that the mRNA reduction actually translates into a loss of protein expression in 
HCT-116 and SW480 cells after an initial screen of many cell lines for detectable levels 
of Nesprin-2 isotypes (Fig. 2.1B and data not shown). There are two Nesprin-2 alternate 
splicing variants that are very close to the observed Nesprin-2 protein size, Nesprin-2α1 
and Nesprin-2α2 (Fig. 2.1C). To help differentiate between the two variants, two sets of 
PCR primers were designed; one that targets both isoforms and another which does not 
recognize Nesprin-2α2. Reverse transcriptase PCR was performed on HCT-116 cells 




Figure 2.2 Microarray conformation of genes down-re gulated by SS. 
 
(A) HCT-116 cells were treated with 30 µM SS for 24 h, and three replicates of reverse 
transcriptase PCR were performed. Representative gel electrophoresis images are 
shown with NAG-1 as a positive control for SS treatment and GAPDH as a loading 
control. Averages of densitometer analysis of mRNA expression levels from the three 
replicates were normalized to GAPDH and compared to the vehicle. The data represent 
mean ± S.E. P-values of **, P < 0.01, and ***, P < 0.001. (B) Schematic showing 
Nesprin-2 isoforms: Giant, α1, and α2. Locations of PCR primers, siRNA targets, and 
shRNA targets are shown. Reverse-transcriptase PCR data shows the effect of 30 µM 
SS for 24 hr using primers specific for Nesprin-2 α1, specific for Nesprin-2 α2, and 
primers which amplifiy most isoforms of Nesprin-2 including: Giant, α1, and α2. Nesprin-
2 Giant specific primers are shown in (A). (C) Western blot analysis of cells treated with 
vehicle or 30 µM SS for 24 hr using anti-Nesprin-2 targeting the C-terminal region. The 







Figure 2.2 Continued. 
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2.4.4 Time- and Dose-Dependent Down-Regulation of Nesprin-2 by several 
NSAIDs 
Nesprin-2 has previously been reported in the leading edge of migrating cells in 
wound-healing assays [97]. Due to this and its structural role, Nesprin-2 is an excellent 
candidate for investigation of the effects of SS on cell morphology and adhesion. 
Nesprin-2 mRNA was suppressed in a time dependent manner with significant 
reductions beginning at 6 h of treatment, p < 0.01 (Fig. 2.3A). Nesprin-2 down-
regulation by SS was also dose dependent, starting with 1 µM up to 30 µM (Fig. 2.3B). 
Next, a range of other NSAIDs was tested to see if Nesprin-2 reduction is unique to SS 
or common among NSAIDs. A wide range of NSAIDs were used including conventional 
NSAIDs, which inhibit both COX-1 and COX-2 (SS, TA, and diclofenac) as well as the 
COX-1 specific inhibitor SC-560 and the COX-2 specific inhibitor DFU. All NSAIDs 
significantly reduced Nesprin-2 mRNA expression at p < 0.05, with the most dramatic 
repression by SS (Fig. 2.3C). Interestingly, SS repression of Nesprin-2 is not limited to 
HCT-116 cells; however, this does not occur in all colorectal cancer cell lines tested. 
Sulindac sulfide treatment for 24 hours significantly reduced Nesprin-2 in HT-29 cells; 
however, SW480 cells showed a reduction in Nesprin-2 with no statistical significance 
(Fig. 2.3D).  
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Figure 2.3. Nesprin-2 mRNA expression in a time and  dose dependent manner. 
 
(A) Nesprin-2 down-regulation by SS was shown by real time PCR to be time-
dependent over a 24 h time course for HCT-116 cells treated with 30 µM SS. (B) HCT-
116 cells also showed a dose dependant response by real time PCR to SS over a 24 h 
treatment. (C) A variety of NSAIDs (SS 30 µM, tolfenamic acid 20 µM, diclofenac 100 
µM, SC-560 25 µM, and DFU 100 µM) were tested on HCT-116 cells for 24 hr (reverse 
transcriptase PCR). (D) Other colorectal cancer cell lines, HT-29 and SW480, were 
tested for Nesprin-2 suppression by reverse transcriptase PCR with SS after 24 hr 
treatments. (E) Reverse transcriptase PCR on HCT-116 cells pre-treated with 5 µM 
actinomycin D for 1 hr prior to a SS time course was performed and lines indicate a 
linear regression trend. Representative reverse transcriptase-PCR data and the 
densitometry results (bottom) as well as real time PCR data are shown from at least 
three independent experiments normalized to GAPDH and compared to 0 hr (A & E) or 











2.4.5 Normal and Tumor Tissue Protein Expression of Nesprin-2 
A tissue array slide containing a range of normal and neoplastic tissues was 
used to study Nesprin-2 protein expression on the microscopic level. The majority of the 
normal and neoplastic tissues in the array did not have detectable levels of positive 
staining, although the antibody detects all isotypes. Increased immunohistochemical 
staining of Nesprin-2 protein was observed in the neoplastic epithelial cells in tissues of 
breast, duodenum, rectum, and thyroid, compared to normal tissue (Fig. 2.4, Table 2.2). 
Focal to diffuse, mild to moderate positive staining was present within the cytoplasm of 
neoplastic cells. Discernible cytoplasmic staining of normal cells was limited to rare foci 
of crypt cells in the rectum. Although Nesprin-2 has been primarily detected in the 
nuclear membrane [97], our data suggest Nesprin-2 expression mostly in cytoplasm. 
This cytoplasmic localization in multiple neoplastic epithelial cells as well as the 




Figure 2.4 Nesprin-2 normal tumor tissue array. 
 
Immunohistochemical staining of Nesprin-2 in human normal and tumor tissue array. 
Slides were stained with Nesprin-2 antibody, seen as brown coloring, and counter 
stained with Hematoxylin. Three independent observers note stain intensity for 47 
normal tissues and 47 tumor tissues (Table 2). Representative images from the tissues 
with the highest expression are shown. The large frames were taken with a 40X 
objective lens (50 µm scale bars), and the small frames in the upper left corners are at 










2.4.6 Cellular Impedance is Reduced by siRNA & shRNA Knock-down of Nesprin-
2 
The micro-impedance experiment was performed on HCT-116 cells either 
transfected with siRNA against Nesprin-2 or non-targeting control siRNA, then treated 
with vehicle or SS. In the case of the SS-treated cells, initial adhesion was similar at first 
for both Nesprin-2 knock-down and non-targeting control cells. After approximately a 
day and a half the Nesprin-2 knock-down cells showed reduced adhesion compared to 
the non-targeting control cells (Fig. 2.5B and C). The average reduction in Nesprin-2 
mRNA when adjusted by GAPDH was a knock-down of 53% (Fig. 2.5A). Normalized 
resistance is representative of cell-cell and cell-substrate adhesion while normalized 
reactance reflects the plasma membrane capacitance. Both normalized resistance and 
reactance in the Nesprin-2 knock-down cells showed a reduction ranging from 50% 
after two days when the cells were most actively growing to 20% at completion of the 
three and a half day experiment as compared with the control siRNA transfected cells 
treated with vehicle (Fig. 2.5B and C). Similar impedance results were generated with 
shRNA targeted against Nesprin-2, though the knock-down was less (Fig. 2.6). This 
suggests that reduction in Nesprin-2 by SS treatment could be contributing to the loss of 
adhesion in colorectal cancer cells. 
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Figure 2.5 The effect of Nesprin-2 mRNA knock-down of HCT-116 on micro-
impedance. 
 
(A) Nesprin-2 expression knock-downed by siRNA. Nesprin-2 siRNA was transfected, 
and subsequently real time PCR was performed in triplicate to validate the siRNA in our 
system. GAPDH was used to amplify for RNA control. The graph shown represents a 
relative fold change, as the control siRNA set is 1.0 from three independent 
experiments. *P < 0.01. (B) Micro-impedance measurement of HCT-116 cells with 
knocked-down Nesprin-2 expression. HCT-116 cells were transfected with non-targeting 
control siRNA or siRNA Nesprin-2 and treated with vehicle or 30 µM SS. (C) The 
corresponding normalized reactance of these same cells was measured at the same 
time during this period. The terms R and X represent the resistance and reactance, 
respectively, and the subscripts c and n indicate cell covered and naked scans, 










Table 2.2 Normal tumor tissue array staining intens ity. 
Immunohistochemical Staining of Nesprin-2 in Normal and Tumor Tissue. 
Immunostaining was performed on a Biochain Tissue Array Human Tumor Tissue II 
(Lot# A711214) using mAB K20-478 antibody against Nesprin-2 and counterstained 
with hematoxylin. Each of the 96 positions was evaluated for staining intensity, 
localization of staining, and the distribution of staining. The staining intensity was scored 
from 0 to 3+. The type of cell stained was also noted where applicable. 
 
Position  Organ  Staining  Localization  Cell Type  Distribution  
A1 Positive Control 0 0 N/A N/A 
A2 Negative Control 0 0 N/A N/A 
A3 Adrenal Tumor 0 0 N/A N/A 
A4 Adrenal 2+ cytoplasm cortical epithelium diffuse 
A5 Adipose Tumor 0 0 N/A N/A 
A6 Adipose 0 0 N/A N/A 
A7 Bladder Tumor 1+ cytoplasm epithelium rare, scattered 
A8 Bladder 1-2+ cytoplasm epithelium occasional 
disseminated 
A9 Bladder Tumor 0-1+ cytoplasm epithelium rare, scattered 
A10 Bladder 1+ cytoplasm epithelium diffuse 
A11 Brain Tumor 1+ cytoplasm glial tumor cells rare, scattered 
A12 Brain 0 0 N/A N/A 
B1 Breast Tumor 0 0 N/A N/A 
B2 Breast 1-2+ cytoplasm epithelium diffuse 
B3 Breast Tumor 0 0 N/A N/A 
B4 Breast 0 0 N/A N/A 
B5 Colon Tumor 0 0 N/A N/A 
B6 Colon 0 0 N/A N/A 
B7 Colon Tumor 0 0 N/A N/A 
B8 Colon 0 0 N/A N/A 
B9 Duodenum 
Tumor 
2+ cytoplasm epithelium, 
glandular 
rare, multifocal, global 
B10 Duodenum 0 0 N/A N/A 
B11 Esophagus 
Tumor 
1+ cytoplasm epithelium rare focal 
B12 Esophagus 0  N/A N/A 
C1 Esophagus 
Tumor 
0 0 N/A N/A 
C2 Esophagus 0 0 N/A N/A 
C3 Esophagus 
Tumor 
0 0 N/A N/A 




Table 2.2 Continued. 
 
Position  Organ  Staining  Localization  Cell Type  Distributio n 
C5 Fallopian Tumor 0 0 N/A N/A 
C6 Fallopian Tube 0 0 N/A N/A 
C7 Gall Bladder 
Tumor 
0 0 N/A N/A 
C8 Gall Bladder 0 0 N/A N/A 
C9 Kidney Tumor 0 0 N/A N/A 
C10 Kidney 0 0 N/A N/A 
C11 Kidney Tumor 0 0 N/A N/A 
C12 Kidney 1+ cytoplasm epithelium occasional 
disseminated 
D1 Liver Tumor 0 0 N/A N/A 
D2 Liver 0 0 N/A N/A 
D3 Liver Tumor 0-1+ cytoplasm  diffuse 
D4 Liver 1-2+ cytoplasm epithelium 1+diffuse, 2+ scattered 
D5 Lung Tumor 1+ cytoplasm epithelium diffuse 
D6 Lung 0 0 N/A N/A 
D7 Lung Tumor 0 0 N/A N/A 
D8 Lung 0 0 N/A N/A 
D9 Lung Tumor 0 0 N/A N/A 
D10 Lung 0 0 N/A N/A 
D11 Lung Tumor 1+ cytoplasm epithelium rare scattered 
D12 Lung 0 0 N/A N/A 
E1 Lung Tumor 1+ cytoplasm  rare scattered 
E2 Lung 0 0 N/A N/A 
E3 Lymphoma 0 0 N/A N/A 
E4 Lymph Node 0 0 N/A N/A 
E5 Lymphoma 0 0 N/A N/A 
E6 Lymph Node 0 0 N/A N/A 
E7 Ovary Tumor 0 0 N/A N/A 
E8 Ovary 0 0 N/A N/A 
E9 Ovary Tumor 0 0 N/A N/A 
E10 Ovary 0 0 N/A N/A 
E11 Pancrease 
Tumor 
1+ cytoplasm epithelium rare scattered 




Table 2.2 Continued. 
 
Position  Organ  Staining  Localization  Cell Type  Distribution  
F1 Parotid Tumor 2+ golgi? plasma cells disseminated 
F2 Parotid 0 0 N/A N/A 
F3 Prostate Tumor 0 0 N/A N/A 
F4 Prostate 0 0 N/A N/A 
F5 Rectum Tumor 0 0 N/A N/A 
F6 Rectum 0 0 N/A N/A 
F7 Rectum Tumor 1+ cytoplasm cytoplasm locally diffuse 
F8 Rectum 0 0 N/A N/A 
F9 Skin Tumor 0 0 N/A N/A 
F10 Skin 1+ cytoplasm basal epithelium locally diffuse 
F11 Small Intestine 
Tumor 
1+ cytoplasm epithelium rare scattered 
F12 Small Intestine 0 0 N/A N/A 
G1 Soft Tissue 
Tumor 
0 0 N/A N/A 
G2 Soft Tissue 0 0 N/A N/A 
G3 Stomach Tumor 0 0 N/A N/A 
G4 Stomach 1+ cytoplasm glandular 
epithelium 
disseminated 
G5 Stomach Tumor 0 0 N/A N/A 
G6 Stomach 0 0 N/A N/A 
G7 Stomach Tumor 0 0 N/A N/A 
G8 Stomach 0 0 N/A N/A 
G9 Testis Tumor 0 0 N/A N/A 
G10 Testis 1+ cytoplasm inerstitial cells diffuse, may be an 
artifact 
G11 Throat/Ph. Tumor 0 0 N/A N/A 
G12 Throat/Pharynx 0 0 N/A N/A 
H1 Throat/Ph. Tumor 1+ golgi? plasma cells  
H2 Throat/Pharynx 0 0 N/A N/A 
H3 Thymus Tumor 0 0 N/A N/A 
H4 Thymus 0 0 N/A N/A 
H5 Thyroid Tumor 1+ cytoplasm epithelium diffuse 
H6 Thyroid 0 0 N/A N/A 
H7 Thyroid Tumor 0 0 N/A N/A 
H8 Thyroid 0 0 N/A N/A 
H9 Uterus Tumor 0 0 N/A N/A 
H10 Uterus 0 0 N/A N/A 
H11 Uterus Tumor 0 0 N/A N/A 




Figure 2.6. The effect of Nesprin-2 mRNA knock-down  of HCT-116 on micro-
impedance. 
 
(A) Nesprin-2 expression knock-downed by shRNA. Nesprin-2 shRNA was transfected, 
and subsequently RT-PCR was performed in triplicate for each of the three micro-
impedance measurements, with the same cells used to inoculate the electrodes for the 
micro-impedance measurements. A representative RT-PCR gel from three independent 
experiments is shown. GAPDH was used to amplify for RNA control. The graph shown 
in the bottom represents a relative fold change, as the empty vector set is 1.0 from three 
independent experiments. P-values of **, P < 0.01. (B) Micro-impedance measurement 
of HCT-116 cells with knocked-down Nesprin-2 expression. HCT-116 cells were 
transfected with empty vector or shRNA Nesprin-2 and treated with vehicle or 30 µM 
SS. (C) The corresponding normalized reactance of these same cells was measured at 
the same time during this period. The terms R and X represent the resistance and 
reactance, respectively, and the subscripts c and n indicate cell covered and naked 










There are several well-known methods to examine cell proliferation and 
morphological changes under specific treatments including fluorescence microscopy, 
flow cytometry, and biochemical assays. While these methods are stationary and need 
fluorescent or radioactive probes, micro-impedance measurement is a bio-analytical 
technique that is capable of non-invasively and dynamically monitoring proliferation in 
real time without the use of chemical probes. The use of micro-electrodes to measure 
cellular impedance was pioneered by Giaever and Keese [108, 109]. Since then, this 
technique has been applied to a number of biological studies that deal with cellular 
barrier function, attachment, spreading, and adhesion [110-115].  In addition, frequency-
dependent electrical impedance measurements have been used to evaluate the model 
parameters associated with cell-cell and cell-matrix junction formation [116-118]. In the 
present study, micro-impedance measurements were used to quantitatively examine 
proliferation and morphological changes such as cell-cell adhesion and cell-substrate 
adhesion under different concentrations of SS. Our data demonstrated the suppression 
of cell-cell and cell-substrate adhesion by SS in a dose-dependent manner. 
Subsequently, DICM was performed to observe cell morphology. Unlike phase contrast 
microscopy (PCM), DICM can visualize a wide variety of specimens such as very thin 
filaments, thick specimens, and sharp interfaces and can create realistic 3-dimensional 
shapes as an effective tool to qualitatively and quantitatively examine the effects of anti-
tumorigenic compounds on cell adhesion. IRCM has been well known to provide a more 
comprehensive examination of cellular bottom morphology responses  when exposed to 
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drugs. Early use of IRCM in cell biology goes back to Curtis’ examination of how cells 
adhered to glass [119]. Subsequently, other groups improved this method by using a 
high numerical aperture objective lens, while a theoretical analysis attempted to quantify 
cell substrate separation distances [120, 121].  
Microarrays were performed and two genes were identified as commonly down-
regulated genes, based on biogenesis and cell organization pathways. The IDH2 and 
Nesprin-2 genes represent potential targets of SS since the IDH2 and Nesprin-2 mRNA 
seen in our microarray studies are confirmed by PCR. The fold reductions in these two 
genes observed through multiple replications of PCR correlates with the microarray data 
in that Nesprin-2 is more strongly down-regulated than IDH2 in both cases. Nesprin-2 
was selected for this study based on its unique role as a link between the actin 
cytoskeleton and the nuclear envelope as well as its novelty in relation to cancer. 
Interestingly, Nesprin-1 did not show any alterations in the presence of SS (Fig. 2.4.6A), 
indicating that NSAIDs affect Nesprin-2 in a specific manner.  
While the NSAID doses used in this study were much too high for serum 
relevancy, they were modest compared to other colorectal studies due to the higher 
concentrations obtainable in the colon. Sulindac is converted to the active metabolite 
SS in the liver and travels back to the gut through bile ducts where it is concentrated. 
Also, the natural colonic bacteria converts a large portion of sulindac to SS [122]. These 
two factors suggest that orally administered sulindac can lead to luminal SS 
concentrations in the colon that are higher concentrations than obtainable in serum 
[123]. Human familial adenomatous polyposis (FAP) patients can achieve 10-15 µM 
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plasma concentrations of SS at doses that regress polyps [124, 125]. Animal studies 
have demonstrated that SS concentration in the colon mucosa is many-fold higher than 
serum levels [126]. The cells of the colonic epithelium could be subject to SS 
concentrations as high as 20-fold above what can be observed in the serum [123]. 
Based on the tissue to plasma level ratio of SS in the colon of 10-20 [123, 126], other 
groups have justified using much higher SS concentrations, as high as 100-200 µM, as 
plausible in the human colon [127, 128]. Therefore, our doses used in this study could 
be in the range of clinical doses occurring in the gut. 
Nesprin-2 has previously been reported to be present on the leading edge of 
migrating cells in wound-healing assays [97]. Due to this and its structural role, Nesprin-
2 is an excellent candidate for investigation of the effects of SS on cell morphology and 
adhesion. Nesprin-2 mRNA expression is reduced by SS treatment in a time- and dose- 
dependent manner (Fig. 2.4.6). Other NSAIDs conventional as well as COX 1 and COX 
2 specific all show reductions in Nesprin-2, with the most dramatic repression by SS. 
Interestingly, SS repression of Nesprin-2 is not limited to HCT-116 cells; however, this 
does not occur in all colorectal cancer cell lines tested. It has been reported that β-
catenin participates in modulating cytoskeletal dynamics in association with the 
microfilament-bundling protein fascin [129]. SW480 cells (active β-catenin signaling) did 
not show a significant reduction of Nesprin-2 in the presence of SS (Fig. 2.4.6B and 
2.4.7D), probably explained by the cell context, whereas HCT-116 and HT-29 cells 
possess a mutant β-catenin gene. Therefore, β-catenin signaling may inhibit SS-
dependent Nesprin-2 down-regulation. However, further studies may be required to 
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elucidate the molecular mechanism by which SS down-regulates Nesprin-2 in a cell-
specific manner.  
In the present study, siRNA consistently reduced Nesprin-2 mRNA expression by 
an average of 53%. This reduction in Nesprin-2 mRNA expression correlated nicely with 
the reduction in cell-cell and cell-substrate adhesion seen in the normalized resistance 
and cell’s plasma membrane capacitance seen in the normalized reactance of the 
Nesprin-2 knockdown cells, as compared with the control siRNA-transfected cells 
treated with vehicle. In the case of the SS-treated cells, initial adhesion was similar at 
first for both Nesprin-2 knockdown and control siRNA cells. The Nesprin-2 knockdown 
cells showed reduced adhesion compared to the control siRNA cells. This suggests that 
reduction in Nesprin-2 by SS treatment could contribute to the loss of adhesion in 
colorectal cancer cells.    
Expression of Nesprin-2 in most tissues was too low to be routinely detected by 
immunohistochemistry using standard light microscopy, although the antibody used 
detects all isotypes. Notably increased staining for Nesprin-2 expression in tumor 
tissues over normal tissue can be seen in mammary, duodenal, rectal, and thyroid 
tissues. Although Nesprin-2 has been primarily detected in the nuclear membrane [97], 
our data suggest Nesprin-2 expression mostly in cytoplasm of tumor tissue. This 
cytoplasmic localization in multiple neoplastic epithelial cells as well as the proliferative 
crypt cells of the rectum supports Nesprin-2’s potential role as an oncogene. To the best 
of our knowledge, this is the first report that Nesprin-2 is more highly expressed in tumor 





The present study suggests that Nesprin-2 could be involved in oncogenesis and 
that SS treatment reduces its expression. This is strengthened by the increased 
Nesprin-2 expression observed in several different tumor types compared to normal 
tissue. This is further supported by Nesprin-2 knock-down cells mimicking the cell-cell 
and cell-substrate adhesion patterns seen with SS treatment proportional to the amount 
of suppression. Nesprin-2’s vast size and position on the nuclear envelope and 
cytoplasm mark it as potential scaffolding for many other protein-protein interactions. 
Further study of Nesprin-2 could lead to a novel target for cancer treatment. 
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CHAPTER 3 CHAPTER III 
A NOVEL COX-INDEPENDENT MECHANISM OF SULINDAC SULFI DE 





3.1  Abstract 
Non-steroidal anti-inflammatory drugs (NSAIDs) are extensively used over the 
counter to treat headaches and inflammation as well as clinically to prevent cancer 
among high-risk groups. The inhibition of cyclooxygenase (COX) activity by NSAIDs 
plays a role in their anti-tumorigenic properties. NSAIDs also have COX-independent 
activity which is not fully understood. In this study, we report a novel COX-independent 
mechanism of sulindac sulfide (SS), a conventional NSAID, which facilitates a 
previously uncharacterized cleavage of epithelial cell adhesion molecule (EpCAM) 
protein. EpCAM is a type I transmembrane glycoprotein that has been implemented as 
an over-expressed oncogene in many cancers including colon, breast, pancreas, and 
prostate. We found EpCAM to be regulated by SS in a manner that is independent of 
COX activity. Our findings demonstrate that SS drives cleavage of the extracellular 
portion of EpCAM near the N-terminus. This SS driven cleavage is blocked by deleting 
amino acids 55-81, as well as by simply mutating arginine residues at positions 80 and 
81 to alanine. Proteolysis of EpCAM by NSAIDs may provide a novel mechanism by 




3.2  Introduction 
Non-steroidal anti-inflammatory drugs (NSAIDs) have been used for the 
treatment of inflammatory diseases, but a body of evidence suggests that NSAIDs 
exhibit anti-tumorigenic activity [130-133]. The mechanisms involve both 
cyclooxygenase (COX) dependent and independent pathways; much attention is paid to 
COX-independent manner. Our lab and others have reported several targets of NSAIDs 
in a COX-independent manner [134, 135]; however, more molecular targets of NSAIDS 
are needed to understand the nature of NSAIDs in anti-tumorigenesis. 
Epithelial cell adhesion molecule (EpCAM) is a type I transmembrane 
glycoprotein. Initial studies focused on its role as a Ca+2 independent homophilic 
adhesion molecule [136]. The extracellular region of EpCAM contains two epidermal 
growth factor (EGF)-like domains which are involved in both reciprocal interactions 
between EpCAM molecules on adjacent cells, and lateral interactions between EpCAM 
molecules [136]. In addition, EpCAM can interfere with E-cadherin’s interaction with the 
cytoskeleton [137]. As the protein expression of EpCAM increases it becomes the 
dominate adhesion molecule as it diminishes cadherin-mediated cell-cell adhesions 
[137]. Thus, this transition from cadherin to EpCAM mediated cell adhesion could be 
important to early tumor progression. 
More recent focus has been on EpCAM’s involvement in cancer progression and 
invasion. There are many reports showing EpCAM expressed at high levels in many 
cancer types including gastric, intestinal, colorectal, ovarian, and others [138-142].  
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Down-regulation of EpCAM in gastric cancer cells which overexpress EpCAM inhibits 
proliferation [139]. EpCAM is transcriptionally repressed by the tumor suppressor p53 in 
breast cancer [143]. Increased proliferation observed in conjunction with high EpCAM 
expression could be due in part to its regulation of cell cycle progression through Cyclin 
D1 expression [144]. Furthermore, EpCAM expression in EpCAM negative cells has 
been shown to be involved in epithelial to mesenchymal transition (EMT) [145, 146]. 
Interestingly, EpCAM may act as protagonist or antagonist depending upon the specific 
context within complex biological systems. EpCAM which is widely viewed as an 
oncogene due to its role in early tumor development may be beneficial as an adhesion 
molecule in later stages of cancer progression. For example, a few studies have 
suggested that loss of EpCAM expression is associated with poor patient prognosis and 
is favorable to metastasis [147-150]. Most of the research currently being done on 
EpCAM focuses on either using it as a cancer biomarker [151] or as a target for 
therapeutic antibodies [152, 153]. EpCAM’s biological activity in cancer in the context of 
tumor stage and specific cellular micro-enviroment needs to be elucidated to 
understand EpCAM’s potentially dynamic role in tumor progression.   
One of the pathways that EpCAM affects in tumorigenesis is an alternate Wnt 
signaling pathway. It has been shown that EpCAM can bind to β-catenin through a 
complex with four and a half limb domain 2 (FHL2) [154]. This complex is released from 
the interior of the cell membrane and can translocate to the nucleus and initiate 
downstream TCF/LEF signaling, following proteolysis of EpCAM’s extracellular domain 
(EpEX) then cleavage of EpCAM’s intracellular domain (EpICD) [155]. Recently, 
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EpCAM has been shown through new detailed study of multiple antibodies, to express 
multiple proteolytic fragments [156]. Thus, EpCAM is not only a biomarker of cancer 
cells, but also exhibits multiple biological activities that needed to be elucidated.  
Our group focused on NSAID-effects on anti-tumorigenesis. We found that the 
NSAID SS dramatically decreases EpCAM’s expression via facilitating one of the 
cleavage sites on the extra-cellular region of EpCAM. In this study, we suggest that SS 
affects many pathways and one such novel mechanism is SS’s cleavage of EpCAM. 
 
3.3 Materials and Methods 
 
3.3.1 Reagents 
The NSAIDs used in this study were purchased as follows: SS, TA, and SC-560 
from Cayman Chemical Company (Ann Arbor, Michigan); diclofenac from Sigma-Aldrich 
(St. Louis, MO); 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-ethylsulfonyl)phenyl-2(5H)-
furanone (DFU) was as a gift from Merck (Rahway, NJ). All other chemicals were 
purchased from Fisher Scientific, unless otherwise specified. 
 
3.3.2 Cell Culture 
All cells were purchased from ATCC and grown at 37oC with 5% CO2. HCT-116 
and HT-29 cells were cultured with McCoy’s 5A modified. HCT-116 cells were kept to 
fewer than 20 passages to maintain the expected phenotype. SW480 cells were 
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cultured with RPMI-1640 medium. LoVo cells and A549 cells were cultured with Ham’s 
F12 medium. HepG2 cells were cultured with DMEM medium. Each cell line used was 
not passaged for longer than three months before retrieving fresh cells from liquid 
nitrogen stock to preserve the expected phenotypes. All culture media was 
supplemented with 10% fetal bovine serum, 100 µg/ml streptomycin, and 100 UI 
penicillin. Serum free media was used for all SS and vehicle treatments unless stated 
otherwise. 
 
3.3.3 Reverse Transcriptase PCR and Real Time PCR 
RNA was isolated from cell cultures using Qiagen’s RNeasy Mini Kit following the 
manufacturer’s protocol. One microgram of RNA was used to generate cDNA using 
BIORAD’s iScript™ cDNA Synthesis Kit following the manufacturer’s protocol. PCR was 
performed with the following primers:: EpCAM forward 5’- CTG CCA AAT GTT TGG 
TGA TG -3’; EpCAM reverse 5’- ACG CGT TGT GAT CTC CTT CT -3’; GAPDH 
forward, 5’- GGG CTG CTT TTA ACT CTG GT -3’, GAPDH reverse 5’- TGG CAG GTT 
TTT CTA GAC GG -3’; NAG-1 forward 5’-CTC CAG ATT CCG AGA GTT GC -3’, and 
NAG-1 reverse 5’-AGA GAT ACG CAG GTG CAG GT -3’. Densitometric analysis of 
reverse transcriptase PCR was performed using Scion Image software (Frederick, MD). 
Real Time PCR was performed using Thermo Scientific’s Absolute qPCR SYBR Green 
Mix (Waltham, MA) on a Bio-Rad MyiQ iCycler thermal cycler using Bio-Rad iQ5 version 
2.1 software following the manufacture's protocol (Hercules, CA). Measurements were 




3.3.4 Expression Vectors 
All expression vectors where generated from pcDNA3.1 V5/His TOPO TA 
(Invitrogen Life Technologies, Carlsbad, CA). Primers used include (deleted regions are 
marked [x]): EpCAM-full-F 5’- GCC ACC ATG GCG CCC CCG CAG GTC CTC -3’, 
EpCAM-full-R 5’- TGC ATT GAG TTC CCT AT -3’, EpCAM-Top-iFLAG-F 5’- T GCC 
GCA GCT GAT TAC AAG GAT GAC GAC GAT AAG CAG GAA GAA TGT GTC -3’, 
EpCAM-Bot-iFLAG-R 5’- CA TTC TTC CTG CTT ATC GTC GTC ATC CTT GTA ATC 
AGC TGC GGC AAA AGT CG -3’, EpCAM-53-77-F 5’- T GGT GCA CAA [x] GGC TCA 
AAA CTT GGG AGA AGA GCA AAA CC -3’, EpCAM-53-77-R 5’- G TTT TGA GCC [x] 
TTG TGC ACC AAC TGA AGT ACA CTG GC -3’, EpCAM-53-58-F 5’- T GGT GCA 
CAA [x] AAG CTG GCT GCC AAA TG -3’, EpCAM-53-58-R 5’- C AGC CAG CTT [x] 
TTG TGC ACC AAC TGA AGT ACA C -3’, EpCAM-59-65-F 5’- C ATT TGC TCA  [x] 
GTG ATG AAG GCA GAA ATG AAT GGC TC -3’, EpCAM-59-65-R 5’- C CTT CAT 
CAC [x] TGA GCA AAT GAC AGT ATT TTG TGC ACC -3’, EpCAM-66-72-F 5’- C AAA 
TGT TTG [x] GGC TCA AAA CTT GGG AGA AGA GCA AAA CC -3’, EpCAM-66-72-R 
5’- G TTT TGA GCC [x] CAA ACA TTT GGC AGC CAG CTT TGA GC -3’, EpMUT-RR-
AA-F 5’- GGC TCA AAA CTT GGG GCA GCA GCA AAA CCT GAA GGG GC -3’, 






The cells were seeded on 35 mm glass bottom plates (MatTek Corp., P35G-1.5-
10-C, Ashland, MA, USA) and grown in culture media for 48 hours. The cells were 
washed twice with PBS, fixed with ice-cold acetone for 15 min, and washed in PBS for 
five minutes three times. Non-specific binding of the antibodies was blocked by 
universal blocking solution (Biogenex, San Ramon, CA) for 30 min at room temperature 
and the cells were incubated with a mixture of specific antibodies for FLAG-tag (1:250) 
(Rockland, 600-401-383) and V5-tag (1:250) (AbD Serotech, MCA1360GA) overnight at 
4°C. The cells were washed with PBS containing 0.1% Tween 20 (PBS-T) for five 
minutes three times and incubated with secondary antibodies goat anti-mouse TRITC 
conjugate (1:250) (Southern Biotech, 1032-03) and goat anti-rabbit Alexa Fluor 488 
(1:300) (Invitrogen, A11008) for one hour covered at room temperature. The nucleuses 
were counter-stained with 0.5 mg/mL of DAPI for two minutes and then washed for five 
minutes with PBST three times. The slides were mounted with a few drops of an 
aqueous mounting medium after the excess PBST was decanted. A fluorescence 
microscope was used to detect protein expression of  (Nikon, Eclipse E600, Melville, 
NY, USA). QCapure software version 2.66.4 was used to capture tif images at a 400x 
magnification. 
 
3.3.6 Western Blot 
Cells lysates were isolated in RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM 
NaCl, 1 mM EDTA, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS) 
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supplemented with protease inhibitors (1mM PMSF, 1 µg/mL aprotinin, 1 µg/mL 
leupeptin) and phosphatase inhibitors (10 mM NaF, 0.1 mM Na3VO4,).  Protein 
concentration was determined by BCA protein assay (Pierce, Rockford, IL). The 
proteins were separated on SDS–PAGE and transferred to nitrocellulose membranes 
(Osmonics, Minnetonka, MN). The membranes were incubated in primary antibody 
diluted in 5% milk made with TBS-T at 4°C overnight. The antibodies used in this study 
include: anti-EpCAM (CBL251, Chemicon International/Millipore, Billerica, MA ); anti-
Actin (sc-1615), anti-EpCAM (sc-51681), and anti-V5 from Santa Cruz Biotechnology 
Inc. (Santa Cruz, CA); anti-NAG-1 which was generated previously [134]; anti-β-catenin 
(BD Biosciences, San Jose, CA); anti-FLAG (600-401-383, Rockland Immunochemicals 
Inc., Gilbertsville, PA), anti-Cyclin D1(#2978S), anti-E-cadherin (#3195S) from Cell 
Signaling Technology (Danvers, MA). After three washes with tris buffered saline 
containing 0.05% Tween 20, the blots were incubated with peroxidase-conjugated IgG 
for one hour at room temperature and visualized using ECL (Amersham Biosciences, 
Piscataway, NJ) and a LAS-4000 mini (Fujifilm Life Sciences, Stamford, CT). 
 
3.3.7 3-D Spheroid Cell Invasion Assay 
HCT-116 stable cells, EpCAM wt and EpCAM mut, were seeded into round 
bottom 96 well plates at 3,000 cells per well in 50 µl of 1x spheroid formation ECM 
medium following the manufacture’s protocol (Cultrex, 96 Well 3D Spheroid BME Cell 
Invasion ASsay, 3500-096-K). Two of the treatment samples had 30 µM SS added to 
the 1x spheroid formation ECM medium at the time of plating as well as after formation 
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of the invasion matrix and two treatment samples only had 30 µM SS treatment added 
to the growth medium beginning after setting up the invasion matrix. The cells were 
allowed 72 hours for spheroid formation, then the invasion matrix was formed according 
the Cultrex’s protocol. Following invasion matrix formation, medium containing 5 µM 
EGF or vehicle and 30 µM SS or vehicle was added to the top and spheroids where 
observed for 10 days post-invasion matrix and treatment. 
 
3.3.8 Statistics 
Unless stated otherwise statistical significance was determined using single-
tailed paired Student t tests. P-values are noted with asterisks as follows: *P < 0.05, **P 




3.4.1 NSAIDs alter EpCAM expression.  
HCT-116 cells were screened for reduction of EpCAM protein by various NSAIDs 
including: SS, diclofenac (Diclo.), aspirin (Asp.), TA, and 5,5-dimethyl-3-(3-
fluorophenyl)-4-(4-methylsulphonyl)phenyl-2(5H)-furanone) (DFU) (Fig. 3.1A). SS and 
TA both showed marked reduction in EpCAM protein expression (Fig. 3.1A). SS was 
selected for further study due to its more dramatic effect. HCT-116 cells showed both a 
time and dose dependent loss of EpCAM expression from SS treatment (Fig. 3.1B and 
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C). Several other cell lines including the human colorectal cancer cell lines HT-29, 
LoVo, and SW480, the human lung carcinoma cell line A549, and the human 
hepatocellular carcinoma cell line HepG2 were screened for EpCAM reduction by SS 
(Fig. 3.1D). All cell lines which had detectable EpCAM expression except A549 cells 
showed reduction of EpCAM by SS (Fig. 3.1D). Interestingly, SS treatment at the levels 
used here did not decrease EpCAM expression in SW480 cells, which we have 
observed to be more resistant to SS treatment and require higher concentrations of SS 





Figure 3.1 NSAIDs effect EpCAM protein expression.   
(A) Western blot screen of HCT-116 cells with NSAIDs (30 µM: sulindac sulfide, 
diclofenac, aspirin, tolfenamic acid, and 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-
methylsulphonyl)phenyl-2(5H)-furanone) for effects on EpCAM protein expression. 
NAG-1 is shown as a positive control. (B) Western blot of EpCAM protein expression in 
HCT-116 cells treated with sulindac sulfide in incrementally increasing doses. (C) 
Western blot of EpCAM protein time course with 30 µM sulindac sulfide treatment. (D) 
Western blot of EpCAM protein expression under 30 µM sulindac sulfide treatment in 




3.4.2 SS affects EpCAM expression independent of transcriptional regulation, 
kinase activity, or proteasomal degradation pathway.  
EpCAM mRNA expression was measured by reverse-transcriptase PCR under 
various SS doses, all of which demonstrated no significant effect of SS treatment on 
EpCAM mRNA expression (Fig. 3.2A). Next, inhibitors for various kinase pathways 
including CKII, EGFR, JAK2, GSK-3, MEK/ERK, PI3K, JNK, PKC, p38 MAPK, and 
mTOR were screened for rescue of EpCAM expression in the presence of SS (Fig. 
3.2B). None of these were able to restore EpCAM to vehicle levels, though a few 
including PI3K, JNK, and PKC showed a very slight increase in EpCAM compared to 
SS without kinase inhibitor pretreatment (Fig. 3.2B). Then the possibility of SS action on 
EpCAM through proteasomal degradation pathways was explored with several 
inhibitors. HCT-116 cells were pretreated with Ada-vinyl sulphone, lactacycine, 
epoxomicin, MG132, and YU102; however, none of these were able to even partially 
protect EpCAM from loss by SS treatment (Fig. 3.2C). These results indicate that SS-
mediated EpCAM down-regulation is not mediated by transcription regulation, kinase 





Figure 3.2 SS effects EpCAM protein expression in a  manor independent of 
transcriptional regulation, kinase activity, or pro teasomal degradation. 
(A) Sulindac sulfide’s effect on EpCAM mRNA expression visualized by reverse 
transcriptase polymerase chain reaction in HCT-116 cells. Densitometric fold change 
relative to vehicle is shown below the gel pictures. (B) Western blot screen of various 
kinase inhibitors for rescue of EpCAM protein expression under 30 µM sulindac sulfide 
treatment (4,5,6,7-tetrabromobenzotriazol 5 µ, AG490 50 µM,  lithium chloride 10 mM, 
PD98059 40 µM, Wortmannin 0.5 µM, SP600125 10 µM, RP-318220 2.5 µM, 
SB203580 10 µM). (C) Western blot screen of proteasomal degradation inhibitors for 
rescue of EpCAM protein expression under 30 µM sulindac sulfide treatment (adavinyl 




3.4.3 SS facilitates a specific cleavage of EpCAM at the N-terminal region.  
In order to investigate how SS reduces EpCAM expression, full-length EpCAM 
was cloned into pcDNA3.1 V5/His/TOPO/TA vector. This provided C-terminal V5 and 
polyhistidine tags. Subsequently, we used site-directed mutagenesis to insert FLAG tag 
at the N-terminal region of EpCAM, right after the signal peptide to prevent the tag from 
being cleaved with the signal peptide during processing (Fig. 3.3A). After transfecting 
into HCT-116 cells, the FLAG tag expression pattern under SS treatment is similar to 
what we observed with the endogenous EpCAM. Interestingly, when we probed with V5 
tag, we observed a specific extra EpCAM band that is smaller than full size and not 
visible with either FLAG antibody or endogenous EpCAM antibody (Fig. 3.3B). This 
band will be referred to as a truncated EpCAM (EpTCAM). EpTCAM is induced by SS 
treatment while full length EpCAM is reduced by SS treatment and total EpCAM 
expression (full length EpCAM and EpTCAM together) is fairly constant under SS 
treatment (Fig. 3.3B).  
To further investigate the role of EpCAM in cancer cells a stable EpCAM-iFLAG-
V5/His cell line was developed in HCT-116 cells. Immunofluorescence staining was 
performed to test this cell line for proper membrane localization. The data exhibited a 
strong overlap of FLAG and V5 signal along the cell membrane, suggesting that full 
length tagged EpCAM is expressed in cell membrane where the majority of it should be 
(Fig. 3.3C). There are portions of the cytoplasm where V5 staining (red) can be seen in 
the absence of FLAG (green) staining; this could indicate the presence of the small 
cleaved EpICD previously reported [155].  
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Next, we further analyzed these EpCAM over-expression cells. The conversion of 
full length EpCAM to EpTCAM by SS occurs in a dose and time dependent manner 
(Fig. 3.3D & Fig. 3.3E). Proteasomal degradation inhibitors were tested again; this time 
to observe the SS’s effect on EpTCAM. As shown in Fig. 3.3F, EpTCAM expression is 
affected by SS and further stabilized EpTCAM in the presence of proteasomal inhibitors. 
Finally we confirmed that EpTCAM is affected by proteasomal degradation pathways, 
as evidence that cycloheximide treatment increases EpTCAM expression in the 
presence of SS (Fig. 3.3G). 
 
 79 
Figure 3.3 Exploring SS/EpCAM interaction through g eneration of a multi-tagged 
expression vector. 
 
(A) Diagram showing locations of tags on the EpCAM-iFLAG/V5-His expression vector 
relative to previously reported EpCAM protein features. Location of EpCAM (VU-1D9) 
antibody is marked on the diagram. (B) Western blot data showing FLAG, V5, and actin 
antibodies blotted against HCT-116 cells transiently transfected with LacZ control vector 
or EpCAM-iFLAG/V5-His vector. A protein ladder is included on the left and arrows 
indicated various protein forms present. (C) Immunofluorescence staining of HCT-116 
cells stable transfected with EpCAM-iFLAG-V5/His construct. The nuclei are stained 
blue in the DAPI panel, EpCAM is green in the FLAG panel, and EpCAM is red in the 
V5 panel. Merged panel shows overlapping FLAG and V5 as yellow. (D-G) Western 
blots of HCT-116 cells stable transfected with EpCAM-iFLAG-V5/His. (D) Cells treated 
with incrementally increasing doses of SS for 24 hours and blotted for V5 tagged 
EpCAM. (E) Time course of cells treated with 30 µM SS for increasing amounts of time 
and blotted for V5 tagged EpCAM. (F) Cells pretreated with proteasomal degradation 
inhibitors 5 µM lactacystin, 2.5 µM MG132, and 1 µM YU-102, than treated with 30 µM 
SS for 24 hours. Cells pretreated with 20 µM SS for 9 hours than co-treated with a 
cycloheximide time course and stained for FLAG tagged EpCAM, V5 tagged EpCAM, β-





Figure 3.3 Continued. 
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3.4.4 Determination of SS cleavage site in the EpCAM protein  
To examine which region of EpCAM is affected by SS, we generated several 
deletion constructs based on our full-length FLAG and V5 tagged EpCAM clone (Fig. 
3.4A). First, we deleted the region ranging from amino acids 55 to 81. Then we divided 
this region up into four smaller segments of 6-8 amino acids and made a deletion 
construct for each of these (Fig. 3.4A). All of these constructs were transfected into 
HCT-116 cells and the production of EpTCAM in the presence of SS was examined. As 
shown in Fig. 3.4B, none of the deletion clones produced truncated forms, indicating the 
importance of this entire region (55 to 81) in the production of the truncated form.  
Next, we examined EpCAM expression by SDS-PAGE gel under non-reducing 
conditions. As shown in Fig. 3.4C, we could not find the truncated EpCAM form with V5 
antibody under non-reducing conditions. These results along with previously reported 
structural data indicate that EpCAM has a well-developed tertiary structure including six 
highly conserved di-sulfide bonds in the extracellular domain [157]. A diagram showing 
this structure can be seen in Fig. 3.4C.   
 
3.4.5 Mutation of the suspected EpCAM cleavage site influenced by SS. 
Recently a study by Schnell et al. observed many truncated forms of EpCAM 
including one which appears to be the same size as our SS-induced truncation [156]. 
Therefore, we made point mutations changing this Arg80/Arg81 cleavage site to 
Ala80/Ala81. This construct does not produce truncated EpCAM when transfected into 




Figure 3.4 Deletions to explore potential SS relate d cleavage sites on EpCAM. 
(A) Diagram showing the regions of EpCAM-iFLAG-V5/His construct deleted in black. 
(B) Western blot of HCT-116 cells transiently transfected with EpCAM deletion 
constructs, treated with 30 µM SS and blotted for V5 tagged EpCAM. (C) Reducing 
conditions shows EpCAM without disulfide bonds while the non-reducing conditions 
shows the disulfide bonds intact. Western blot of HCT-116 cells stable transfected with 
empty vector and EpCAM-iFLAG-V5/His treated with 30 µM SS and ran under reducing 




Figure 3.5 Mutation of the suspected EpCAM cleavage  site influenced by SS. 
(A) Diagram of EpCAM protein structure showing cleave site between arginine residues 
at amino acids 80/81 (shown by doted circle). (B) Western blot of HCT-116 cells 
transiently transfected with empty vector, EpCAM-iFLAG-V5/His, or EpMUT-A80A81 
and treated with 30 µM SS for 24 hours. (C) Chart shows fold change in E-cadherin by 
SS compared to vehicle for three experiments. (D) Western blot of wild-type EpCAM 




seems to slightly protect E-cadherin protein expression from down-regulation in the 
presence of SS. This result suggests that EpCAM plays a role in invasion activity and 
the cleavage of this site (80/81).     
 
3.4.6 Biological activity of EpCAM-iFLAG/V5-His (WT) and EpMUT-A80A81 under 
SS treatment. 
It has been reported that EpCAM is linked to invasion and proliferation [158]. SS 
inhibits these biological activities. Therefore, we tested to determine if mutant clone 
(EpMUT-A80/A81) exhibits less sensitivity to SS. Cell proliferation MTS assay was 
performed using three stability transfected HCT-116 cell lines expressing empty vector, 
wild-type EpCAM, or mutated EpMUT-A80/A81 (Fig. 3.6A). The wild-type EpCAM over-
expressing cells showed significantly more grow then either empty vector or mutant 
EpCAM cells (Fig. 3.6A) which is consistent with previous MTS assay data performed 
previous to developing the mutant cell line (data not shown). The mutant cell line 
showed significantly more sensitivity to SS treatment than the either wild-type EpCAM 





Figure 3.6 Biological activity of EpMUT-A80A81 stab le cell line. 
Biological activity of HCT-116 cells stable transfected with empty vector (EV), EpCAM-
iFLAG/V5-His (WT), or EpMUT-A80A81(MUT) under SS treatment. (A) Cell proliferation 
assay, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS), shown as fold change over day 0. The cells were treated with 30 µM 
SS in medium containing 1% serum. 3-D spherical invasion assay comparing WT cells 
and MUT cells (B and C). (B) Comparison of spheroids after forming for 72 hours on 
treatment day 0. (C) SS treatment day 10 after the addition of basement membrane 
invasion matrix. Please note that different microscopes, cameras, and fields of view 





We used a 3-D spheroid invasion assay to observe these stabile cell lines under 
more physiologically relevant conditions. The cells where grown for 72 hours to form the 
spheroids prior to adding the basement membrane matrix and treatments. The Fig. 3.6B 
shows that the spheroids were of comparable size and shape 72 hours after plating on 
treatment day zero. Neither the wild-type EpCAM or the mutant EpCAM cell lines 
produced spindle-like projections in the invasion matrix with or without epidermal growth 
factor (EGF) (Fig. 3.6C). 
 
3.5 Discussion 
EpCAM is a membrane protein and plays an important role in tumorigenesis 
[159]. EpCAM contributes to non-canonical β-catenin pathway by releasing ICD bound 
to β-catenin via FLH2 which can translocate to the nucleus and activate Wnt target 
genes [154, 155]. This is confirmed by using EpCAM KO mice exhibiting congenital 
tufting enteropathy, indicating that EpCAM/β-catenin plays a role in the maintenance of 
intestinal architecture and functionality [160, 161]. Recent data also suggests that 
EpCAM modulates NF-κB activity, thereby increasing invasion activity in breast cancer 
[162], and increases cyclin D1 expression to facilitate cell growth activity [144]. Thus, 
EpCAM plays a pivotal role in tumorigenesis in addition to the role of EpCAM in 
embryonic stem cells.     
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NSAIDs have been used for the treatment of inflammation as well as cancer. 
Among those, SS exhibits a distinctive role in anti-cancer activity. SS is the preferred 
NSAIDs to suppress polyps in familial adenomatous polyposis (FAP) patients and in 
animal models. Mechanistically, SS has been shown to suppress TGF-β induced 
motility of A549 lung adenocarcinoma cells through blocking Akt phosphorylation [163] 
and increasing tumor suppressor NAG-1 in colorectal cancers [16, 27, 164]. In this 
study, SS was selected for further study based on its EpCAM down-regulation 
compared to the other NSAIDs tested and its history in chemotherapy and 
chemoprevention (Fig. 3.1A). The migraine headache medicine TA was another 
interesting NSAID which reduced EpCAM protein expression in a dose-dependent 
manor (data not shown). It has been reported that TA exhibits anti-cancer activity in 
many ways, including induction of apoptotic genes EGR-1, NAG-1, and ATF3 [165, 
166], inhibition of the TGF-β pathway [58]  and NF-κB signaling [167], and inhibition of 
Sp transcription factors [45, 168]. 
EpCAM mRNA is unaffected by SS treatment (Fig. 3.2A) and inhibition of 
proteasomal degradation fails to restore full length EpCAM protein expression (Fig. 
3.2C). Studying SS’s effect on tagged EpCAM allowed us to realize that SS does not 
actually down-regulate EpCAM protein expression, but instead SS facilitates cleavage 
of EpCAM (Fig. 3.3). When EpCAM protein is visualized by western blot using either the 
EpCAM (VU-1D9) antibody or the N-terminal FLAG tag antibody (Fig. 3.3A) it appears 
that SS decreases total EpCAM protein expression. However, upon examination of the 
C-terminal V5 tag on EpCAM it becomes clear that EpCAM protein is still present, but 
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has had a portion of its N-terminal region cleaved leaving the EpTCAM cleavage form 
(Fig. 3.3B). SS drives a shift in the ratio of EpCAM expression from full length EpCAM 
to a shorter cleaved form (EpTCAM), but the overall expression level of full length 
EpCAM and EpTCAM together is not significantly changed.  
In order to better understand SS’s action on EpCAM we needed to narrow down 
the cut site. Based on software which can estimate protein sized from western blot data 
relative to a known standard, we predicted that EpTCAM is 37 kDa. This would put the 
cleavage site near the region between the two EGF-like domains on the extracellular 
portion of EpCAM. We generated deletion constructs from our EpCAM-iFLAG-V5/His 
plasmid to narrow down the region involved. Two large deletions were generated 
deleting EpCAM amino acids 55-81 and 55-74, as well as four smaller 6-7 amino acid 
deletions which break the 55-81 amino acid deletion up into four parts (Fig. 3.4A). Each 
of these deletion clones blocked the generation of EpTCAM (Fig. 3.4B). This region 
could be structurally important for correctly positioning EpCAM for SS driven cleavage.  
The large 55-81 amino acid deletion clone as well as the small 75-81 amino acid 
deletion clone both remove a known EpCAM cleavage site which is not well studied. 
EpCAM has been shown to undergo a cleavage event between arginine 80 and arginine 
81 [169]. EpCAM has 12 highly conserved cysteine residues forming disulfide bonds on 
the extracellular region of EpCAM (Fig. 3.4C). It has been previously shown that under 
non-reducing conditions these disulfide bonds will hold the cleaved 1-80 amino acid 
portion of EpCAM in place in several cancer cell lines including: colorectal, skin, and 
liver [169]. This shows that this cleavage form is not unique to HCT-116 cells. Under 
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normal reducing western blot conditions these disulfide bonds are broken and the 
cleaved 1-80 amino acid portion of EpCAM is lost. To test whether this 80/81 amino 
acid site might be the same site cleaved under SS treatment we ran the same EpCAM-
iFLAG/V5-His lysates treated with either vehicle or SS in both normal reducing 
conditions as well as non-reducing conditions to see if non-reducing conditions would 
eliminate the EpTCAM cleavage form (Fig. 3.4C). Non-reducing conditions showed only 
the full-length form of EpCAM suggesting that the cleaved region is being held in place 
by disulfide bonds under non-reducing conditions. To confirm that this is in fact the SS 
cleavage site, we generated a mutation construct where arginine 80 and arginine 81 are 
changed to alanine 80 and alanine 81 (Fig. 3.5A, dotted circle). This point mutation did 
block generation of the cleaved EpCAM form by SS (Fig. 3.5C). This led to our next 
significant revelation in understanding SS action on EpCAM, that under physiological 
conditions the portion of EpCAM which SS drives cleavage of is not released from the 
protein, but remains tethered by a disulfide bond which complicates the study of this 
system. It would be ideal to overexpress the truncated EpTCAM form to better study its 
biological activity or lack of activity as the case may be, however, an artificial construct 
of 80/81 amino acid cleaved EpCAM would lack the 56 amino acid long region of 
EpCAM anchored by the cysteine bond which could have profound effects on its 
activity.  
While the 3D spheroid invasion assay did not demonstrate the typical spindle-like 
projections of cells invading from the spheroid into through the basement membrane 
matrix, there were clear morphological differences between the wild-type EpCAM cell 
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line and the mutant EpCAM cell line (Fig. 3.6). The mutant cell line showed invasive-like 
growth out from the spheroids while the wild-type cells stayed in much tighter spheroid 
shapes. Curiously, these invasive-like features seemed to be more prominent under SS 
treatment. Observing more invasive properties from the mutant cells than the wild-type 
cells would have made sence if the wild-type cells had shown invasion with EGF 
treatment in the absence of SS. It is possible that HCT-116 cells simply are not invasive 
enough for this assay as they have been previously shown to not be invasive in other 
3D spheroid models [170]. Spheroids still represent an improved in vitro method of 
observing treatment effects on cancer cells by mimicking many of the conditions seen in 
vivo such as formation of cell-cell bonds, hypoxic cores, and increased cell survival 
[171-173]. 
 The Arg80/81 cleavage of EpCAM can be observed in HCT-116 cells without SS 
treatment and has been observed in several cancer cell lines. In the absence of protein 
synthesis EpCAM naturally shifts from full-length form to cleaved form over time and 
this shift is greatly speed up by the addition of SS treatment (Fig. 3.3G). SS driven 
proteolysis of EpCAM could decrease EpCAM protein stability.  
 
3.6 Conclusion 
EpCAM is a complicated protein with many cleavage forms and the potential for 
many biological outcomes. It has been implicated in both positive and negative roles in 
many cancer types depending on the stage and context of its expression. Initially this 
study suggested that SS down-regulated EpCAM protein expression in a manner that is 
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independent of: COX activity, transcription, de novo protein synthesis, and proteasomal 
degradation. Further analysis using EpCAM, which carries an N-terminal FLAG tag and 
a C-terminal V5 tag, revealed that this is not exactly the case. SS is acting on EpCAM in 
a manner independent of the above mentioned pathways; however, EpCAM protein 
expression is not down-regulated. Instead SS facilitates a poorly understood cleavage 
of EpCAM between arginine residues 80 and 81. Mutation of these residues resulted in 
the loss of EpCAM with a truncation at 80/81. Also, deletion of this site and the 
neighboring region resulted in a loss of truncated EpCAM. The realization that SS is 
driving EpCAM arginine 80/81 cleavage also brought the revelation that under 
physiological conditions the truncated portion of EpCAM is still tethered to the 
membrane-bound EpCAM by disulfide bonds bridging highly conserved cysteine 
residues. We have discovered a novel COX-independent mechanism of action for 








NSAIDs interact with many pathways in cancer cells. There are many promising 
cyclooxygenase-independent mechanisms utilized by NSAIDs which provide potential 
avenues for developing new and better drugs that minimize or eliminate the undesirable 
side effects of cyclooxygenase inhibition such as gastric bleeding and cardiovascular 
risks. NSAIDs up-regulate a number of transcription factors such as the tumor 
suppressors EGR-1, ATF3, and CHOP, and down-regulate oncogenic transcription 
factors Sp1 and β-catenin.  
This study demonstrates that multiple Nesprin-2 isoforms are down-regulated by 
SS and Nesprin-α2 is confirmed at the protein level. Knock-down of Nesprin-2 reduced 
cell-cell and cell-substrate adhesion as well as reducing plasma membrane potential in 
human CRC cells. Immunostaining of Nesprin-2 in human normal vs tumor tissues 
showed higher and more frequent staining in tumor tissue compared to normal in many 
tissue types. 
Next we demonstrated that SS modulates the adhesion protein EpCAM at the 
post-translational level. Mutation of EpCAM amino acids 80 and 81 from arginine to 
alanine blocks truncation by SS demonstrating that this is the specific cut site. Deletion 
of the 55-81 amino acid region of EpCAM disrupts the tertiary protein structure and 
blocks SS-driven cleavage of the EpCAM 80/81 site. Thus, Nesrpin-2 represents a 
novel NSAID target and potential cancer-associated protein and EpCAM cleavage 
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